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CHAPTER 1 
INTRODUCTION 
Background 
Acetylcholine plays a major role as a neurotransmitter and neuromodulator 
throughout the central nervous system (CNS) as well as multiple peripheral systems (1, 
2).  In the CNS, cholinergic sources include local interneurons found in multiple brain 
regions, projections originating from the brainstem pedunculopontine and lateral dorsal 
tegmental nuclei as well as from the basal forebrain nuclei (1). The latter provides long-
range cholinergic projections and is the major source of acetylcholine in the neocortex, 
hippocampus and amygdala (Figure 1A), brain regions important in learning and memory.  
Acetylcholine can signal through two distinct classes of receptors that include 
ligand-gated cation channels, termed nicotinic acetylcholine receptors, and G-protein-
coupled muscarinic acetylcholine receptors (mAChRs). While both receptor classes play 
important roles in central and peripheral systems, in the CNS, acetylcholine acts primarily 
through mAChRs as a neuromodulator to shape ensembles of neurons and alter neuronal 
firing in response to changing environmental conditions (1, 3), The five member mAChR 
G-protein coupled receptor (GPCR) family consist of M1, M3 and M5, which primarily 
couple to Gq to activate phospholipase C, and M2 and M4, which primarily couple to Gi/o 
to inhibit adenylyl cyclase and modulate ion channels (Fig. 1B).  
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Figure 1: Schematic of cholinergic signaling in the brain.  
(A) Cartoon schematic of cholinergic projection neurons in the rodent brain. (B) M1, M3, 
and M5 primarily couple to Gαq whereas M2 and M4 primarily couple to Gαi. 
Considerable evidence suggests that mAChRs are critically involved in modulating 
cognition, substance use disorder (SUD) (4, 5) motivation, as well as additional behaviors 
and their localization both pre- and postsynaptically throughout the CNS makes mAChRs 
uniquely situated as potential targets for the treatment of multiple CNS disorders.  
Cognitive disruptions in schizophrenia and Alzheimer’s disease  
Schizophrenia is a devastating psychiatric disorder that afflicts approximately 1% 
of the worldwide population, affects women and men equally, and spans all 
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socioeconomic groups (6). The disease is characterized by three major symptom 
domains: positive, negative, and cognitive symptoms (6–8) . Current antipsychotics are 
effective at treating the positive symptoms such as auditory and visual hallucinations, 
delusions, and disorganized thoughts; however, they do not address the negative or the 
cognitive symptoms. Negative symptoms (e.g. flattened affect, social withdrawal) and 
cognitive symptoms (e.g. deficits in working memory, and cognitive flexibility) are believed 
to be the best predictors of long-term outcome and the costs of treatment along with the 
loss of productivity associated with schizophrenia are estimated to cost the U.S. 
healthcare system over $60 billion per year (8, 9). Additionally, most patients discontinue 
currently available pharmacological treatments due to adverse effects including 
extrapyramidal side effects (EPS) (i.e. dystonia, akathisia, parkinsonism, bradykinesia, 
tremor, and tardive dyskinesia) induced by first-generation typical antipsychotics and 
metabolic side effects (i.e. weight gain, type II diabetes, and hyperlipidosis) induced by 
second generation atypical antipsychotics (10, 11). Therefore, there is a critical need to 
identify and develop novel therapeutic targets for the treatment of the cognitive 
disruptions in patients with schizophrenia.  
 Another well characterized CNS disorder that produces cognitive disruptions is 
Alzheimer’s disease (AD), a debilitating neurodegenerative disorder that afflicts 5.8 
million Americans and this number is believed to grow up to 14 million by the year 2050 
(National Institute on Aging). AD is an irreversible, progressive brain disorder that slowly 
destroys memory and thinking skills, and, eventually, the ability to carry out the simplest 
tasks. In most patients with AD, symptoms first appear in their mid-60s; however there is 
a small subpopulation of patients that develop early onset AD (12). AD is the most 
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common cause of dementia among older adults (13). Dementia is defined by the 
progressive loss of cognitive functioning, thinking, remembering, logic and reasoning and 
these changes result in a dramatically diminished quality of life for the patient as well as 
the caregiver(s) (13, 14). Dementia ranges in severity from the mildest stage, when it is 
just beginning to affect a person’s functioning, to the most severe stage, when the person 
must depend completely on others for basic activities of daily living (13, 14). To date, the 
exact mechanism of action underlying the cause of AD is not known, however, there is 
well established AD-brain pathology that includes an accumulation of intracellular Aβ 
plaques as well as extracellular hyperphosphorylated tau tangles (14).  
Targeting muscarinic acetylcholine receptors for the treatment of AD and 
schizophrenia 
Cholinergic signaling is disrupted in Alzheimer’s disease (AD) and several post-
mortem studies have demonstrated a significant reduction in cholinergic projection 
neurons originating in the basal forebrain of patients with AD (15). Current clinical 
strategies to combat the loss of cholinergic neurons and restore memory and cognition in 
AD include raising total cholinergic tone through systemic administration of 
acetylcholinesterase (AChE) inhibitors that block the breakdown of acetylcholine (16). 
While AChE inhibitors such as tacrine and donepezil have demonstrated dose-dependent 
efficacy in improving cognition in patients with early stage AD, they suffer from dose-
limiting adverse effects attributed to generalized non-selective activation of cholinergic 
receptors in the CNS and periphery, thereby limiting their clinical utility (16). Therefore, 
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there is intense interest in developing more selective agents that activate specific receptor 
subtypes within the cholinergic system. 
Robust preclinical and clinical evidence suggests that mAChRs are critically 
involved in learning and memory (4) and significant investments have been made in 
developing ligands that engage mAChRs for the treatment of cognitive disruptions 
associated with AD, including the nonselective M1/M4 receptor preferring agonist 
xanomeline. In a phase III clinical study in patients with AD, xanomeline significantly 
reduced behavioral disturbances including vocal outbursts, suspiciousness, delusions, 
agitation, hallucinations, and had trending but not statistically significant improvements in 
cognition (17). While the clinical effects were promising, xanomeline has activity on all 
mAChR subtypes and induced severe dose-limiting gastrointestinal (GI) and other 
adverse effects that are mediated by activation of peripheral mAChRs (17, 18). Despite 
these peripheral effects, the promising reduction in behavioral disturbances and the 
trending effect on cognition prompted a small follow up phase II clinical trial in patients 
with schizophrenia (19). Here, xanomeline produced significant improvements in the Brief 
Psychiatric Rating Scale (BPRS, see Glossary), Positive and Negative Syndrome Scale 
(PANSS), and Clinical Global Impression Scale, compared to the placebo-controlled 
group (19). Similar to the AD study, xanomeline produced GI disturbances, which halted 
further clinical development of xanomeline (18, 19). Follow up preclinical studies suggest 
that activation of M2 and M3 in the periphery are responsible for the peripheral adverse 
effects of xanomeline (18). Recently, Karuna Pharmaceuticals renewed interest in 
xanomeline by advancing KarXT, a combination therapy of xanomeline with the 
peripherally restricted mAChR antagonist trospium chloride (20), into a phase II clinical 
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trial for schizophrenia (Clinical Trial Number: NCT03697252). While this combination 
therapy may reduce the adverse effects of xanomeline in the periphery and thereby 
increase the therapeutic window of xanomeline, a more targeted approach selectively 
activating specific mAChRs may provide the greatest clinical benefit.   
Significant investment has been made to develop selective agonists devoid of M2 
and M3, activation including development of the M1 agonist HTL0018318 by Sosei 
Heptares, who recently partnered with Allergan to sponsor a phase I clinical trial for AD 
(Clinical Trial Number: NCT03456349) and phase II trial in patients with Lewy body 
dementia in Japan (JapicCTI-183989) (Table 1). However, an unexpected HTL0018318 
chronic dosing toxicology finding in nonhuman primates placed the clinical trial in Lewy 
body dementia patients on hold (Table 1). Unfortunately, despite major investments in 
medicinal chemistry to develop highly selective M1 or M4 orthosteric agonists, these 
efforts have largely failed due to the highly conserved orthosteric acetylcholine binding 
site among the mAChRs. 
Allosteric modulators of mAChRs  
 In order to develop highly selective small molecules ligands for specific mAChR 
subtypes, several groups have pursued development of allosteric modulators that target 
less well-conserved allosteric sites that are distinct from the orthosteric acetylcholine 
binding site (21, 22). Significant progress has been made in understanding the structural 
basis of allosterism with the determination of the crystal structure for multiple mAChR 
subtypes (23–27), and the crystallization of several state-dependent receptor 
conformations (28). Collectively, the insights into the exact nature of orthosteric and 
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allosteric ligand interactions provided by these crystal structures paired with state-of-the-
art in silico docking of digital compound libraries provide the exciting potential to screen 
large numbers of compounds in very little time and at low cost, thereby identifying new 
chemical scaffolds and novel selective ligands through rational drug design (29, 30).   
Positive allosteric modulators (PAMs) increase responses to orthosteric agonists, 
whereas negative allosteric modulators (NAMs) inhibit responses to orthosteric agonists 
(22). PAMs and NAMs exert their effects by modulating the affinity of an orthosteric ligand 
to the receptor or by modulating coupling to intracellular signaling (22). Follow up 
functional studies, including work utilizing receptor knockout animals have demonstrated 
that the procognitive and antipsychotic-like effects of xanomeline are likely mediated by 
M1 and M4 receptors, respectively (18, 31, 32). Thus, multiple drug discovery efforts have 
focused on developing allosteric modulators for these two mAChR subtypes. 
Potential cognition enhancing effects of M1 PAMs 
The M1 mACh receptor is the most abundant of the five mAChRs in brain regions 
critically involved in cognition such as the prefrontal cortex (PFC) and hippocampus (33, 
34). Pharmacological blockade (35, 36) or genetic deletion (37) of M1 produces profound 
disturbances in learning and memory, including significant deficits in social interaction, 
social discrimination, as well as working memory in the radial arm maze (37). Based on 
these studies, and extensive clinical studies implicating central mAChRs in cognitive 
processing (38–40), selective potentiation of M1 signaling in the CNS using highly 
selective M1 PAMs may hold promise to enhance cognition and reverse learning and 
memory disturbances.  
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 Over the last decade, multiple M1 PAMs have demonstrated robust efficacy in 
several preclinical animal models. Benzyl quinolone carboxylic acid (BQCA), the first 
highly selective M1 PAM to be disclosed, reversed scopolamine-induced memory deficits 
in contextual fear conditioning (41). Interestingly, BQCA also reversed amphetamine 
induced hyperlocomotion (AHL), a common animal model to predict antipsychotic efficacy 
(41). Congruent with this finding, M1 KO mice have an increased response to 
amphetamine, providing direct evidence for regulation of dopaminergic transmission by 
the M1 receptor (42). Together, these findings suggest that M1 PAMs may provide some 
efficacy in treating the positive symptoms of schizophrenia. However, future studies are 
necessary to demonstrate the potential of M1 PAMs to reverse the positive symptoms of 
schizophrenia.  
 This initial BQCA study also revealed insights into the diverse signaling pathways 
that M1 PAMs can potentiate, including ERK phosphorylation and recruitment of β-arrestin 
(41). These ground breaking results were replicated in later studies demonstrating that 
the M1 PAM BQCA can reverse scopolamine-induced deficits in rodents (43) and does 
not display any signal bias in systems expressing wild-type M1 receptors in the presence 
of the endogenous agonist, acetylcholine (44, 45). However, BQCA was demonstrated to 
display a robust signal bias in M1 Designer Receptors Exclusively Activated by Designer 
Drugs (DREADD) receptors that are genetically modified to no longer respond to 
acetylcholine and instead respond to the synthetic agonist clozapine-N-oxide (45). These 
studies suggest that the ligand-receptor dynamics for the muscarinic receptors are more 
complicated than initially thought and careful molecular pharmacology is necessary to 
fully describe each allosteric modulator’s effects on a given receptor.  
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Further characterization of BQCA in native tissue demonstrated that M1 PAMs can 
potentiate the cholinergic agonist carbachol (CCh)-induced increases in spontaneous 
excitatory postsynaptic currents (sEPSCs) onto layer V medial prefrontal cortex (mPFC) 
pyramidal neurons (46). BQCA was also able to potentiate layer V mPFC pyramidal 
neuron inward currents generated by bath application of a subeffective concentration of 
CCh (46). This study also demonstrated the first evidence that M1 PAMs such as BQCA 
may be effective in reversing the learning and memory deficits in Alzheimer’s disease 
evidenced by the ability of BQCA to restore discrimination reversal learning in a 
transgenic mouse model of Alzheimer’s (46). In addition to this interesting finding, BQCA 
was also able to directly modulate non-amyloidogenic amyloid precursor protein 
processing in this same mouse model of AD.  Therefore, M1 PAMs may provide 
symptomatic relief as well as potentially provide disease-modifying effects in patients with 
Alzheimer’s disease. However, further studies are necessary to determine whether M1 
PAMs can have disease modifying effects in other animal models of AD.   
BQCA was also shown to improve acquisition of a visual pairwise discrimination 
task in mice, a highly translatable task to humans (36). In this study, the authors used a 
variant of the visual pairwise discrimination task requiring top-down processing by using 
two objects with unequal salience (36). The ability of BQCA to enhance acquisition of this 
top-down processing task was not surprising since M1 KO mice have impaired acquisition 
of this same visual pairwise discrimination task (36). Another important finding from this 
study was that repeated BCQA administration does not alter M1 mAChR mRNA 
expression in the hippocampus, PFC or striatum. Chronic dosing of small molecules can 
alter transcript and/or protein levels for other receptors, illustrated by some group II mGlu 
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agonists, and these changes in transcript and/or protein levels can result in tolerance and 
loss of efficacy (47). Thus, the lack of change in M1 mAChR transcript levels after chronic 
BQCA dosing further supports M1 PAMs as potentially efficacious therapeutics. However, 
we do not know if this is finding will hold true for all other M1 PAMs, and future studies are 
necessary to confirm this BQCA finding. 
While BQCA has been used extensively as a tool compound in preclinical animal 
studies, BQCA lack suitable “drug like” properties. Therefore, Merck invested 
considerable efforts to develop the next generation of M1 PAMs with improved 
pharmacokinetic properties, selectivity and brain penetrance. These efforts resulted in the 
disclosure of the newer M1 PAM 1-((4-cyano-4-(pyridine-2-yl)piperidin-1-yl)methyl-4-oxo-
4H-quinolizine-3-carboxylic acid) (PQCA), which also demonstrated substantial 
preclinical efficacy by attenuating scopolamine-induced deficits in: novel object 
recognition in rats, self-ordered spatial search in cynomolgus macaques as well as object 
retrieval detour task in rhesus macaques (48). Subsequent studies revealed that PQCA 
also reversed scopolamine-induced deficits in the object retrieval detour cognition task in 
monkeys (49) as well as improved object recognition in the Tg2576 AD mouse model 
alone or in the presence of subeffective doses of donepezil (50). Further support for the 
potential efficacy of M1 PAMs in treating neurodegenerative disorders is evidenced by the 
ability of 2 distinct M1 PAMs to reverse cognitive disruptions in a prion mouse model of 
neurodegeneration (51). In addition to reversing the cognition deficits induced by 
pathogenic prions, the authors in this study demonstrated that chronic M1 PAM dosing 
greatly extended the lifespan of the diseased mice (51).  
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In parallel to Merck’s medicinal chemistry efforts, several other research groups 
including our group at Vanderbilt University as well as teams at Monash University, and 
Pfizer have identified, developed and characterized M1 PAMs for the potential treatment 
of the cognitive disruptions in AD and schizophrenia. The prototypical M1 PAM 
VU0453595 was recently demonstrated to rescue cognitive disruptions in mice treated 
subchronically with phencyclidine (PCP), a commonly used NMDA hypofunction mouse 
model of schizophrenia (52). Mechanistically, VU0453595 was shown to reverse PCP-
induced deficits in a M1-mediated form of synaptic plasticity in the PFC. Important for 
translating brain slice electrophysiological responses to responses in vivo, VU0453595 
potentiated LTD induced by optically-evoked release of acetylcholine in PFC containing 
brain slices (52). Therefore, the effects of M1 PAMs on synaptic plasticity in the brain are 
not solely dependent on introduction of exogenous cholinergic agonists. Additional 
studies using the more potent M1 PAM VU6004256 demonstrated M1 PAM efficacy in 
reversing cognitive disruptions in GluN1 knockdown mice, a genetic mouse model of 
NMDA hypofunction in which expression of the GluN1 subunit of the NMDA receptor is 
greatly reduced (53). To this same end, a study from Monash University demonstrated 
that BQCA could improve the efficacy of antipsychotics in mouse models of schizophrenia 
(54). While these results are very promising, BQCA effectively potentiated subeffective 
doses of atypical but not typical antipsychotics (54) therefore suggesting that M1 PAM 
clinical trials in schizophrenia may be more complicated than originally thought. 
In addition to both Merck and Vanderbilt University, Pfizer has spent considerable 
effort in developing M1 PAMs. The highly selective and potent M1 PAM PF-06764427 
reversed AHL in mice (55). Shortly after disclosure of PF-06764427, Pfizer published 
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studies with PF-06767832, a newer M1 PAM that reversed AHL in rats in a dose-
dependent manner. In this same study, the authors demonstrated that PF-06767832 
could reverse scopolamine-induced deficits in Morris water maze, a commonly used 
spatial learning task (56). While preclinical animal models of schizophrenia suffer from 
many caveats including the lack of construct validity, together, these studies provide 
support for the idea that M1 PAMs may be efficacious in treating the cognitive disruptions 
in patients with schizophrenia.   
Mechanistically, preliminary investigation into how M1 PAMs may exert their 
procognitive effects at the molecular and cellular level have revealed that M1 PAMs can 
potentiate normal synaptic plasticity (52, 57) and neuronal excitability (46) in the PFC and 
can reverse synaptic plasticity disruptions in the PFC. Additionally, several studies have 
demonstrated a role of M1 mAChRs in hippocampal function, since M1 PAMs can 
specifically potentiate synaptic plasticity occurring at the hippocampus-PFC synapse (58) 
and activation of M1 mAChRs in the hippocampus can induce synaptic plasticity (59, 60) 
as well as facilitate spatial reversal learning, an important hippocampal dependent task 
(61).  
The ability of M1 PAMs to improve cognitive deficits in multiple distinct animal 
models as well as in multiple relevant preclinical species provides substantial support for 
the potential for M1 PAMs to exhibit efficacy in reversing deficits in cognition in human 
patients suffering from AD and schizophrenia.  
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CHAPTER 2 
DIVERSE M1 PAM PHARMACOLOGY 
Agonist activity in addition to PAM activity 
While these findings are very promising, recent studies have revealed that some 
but not all M1 PAMs display adverse effects including GI distress and behavioral 
convulsions in rodents and dogs (34, 57, 62). Previously, it was demonstrated that the 
nonselective mAChR orthosteric agonist pilocarpine induced robust seizures in healthy 
adult mice and mice in which M2, M3, M4 or M5 was genetically knocked out (KO) but 
produced no effect in M1-KO mice, suggesting that overactivation of the M1 receptor 
mediates these adverse effects (63, 64). Therefore, one possibility to account for the stark 
contrast between M1 PAMs that produce adverse effects and those that do not is the 
hypothesis that some M1 PAMs can overactivate the M1 receptor and therefore lead to 
similar adverse effects as traditional orthosteric agonists (57, 62, 65, 66). This is 
reminiscent of studies from allosteric modulators for other GPCRs, such as the 
metabotropic glutamate receptor subtype 5 (mGlu5), which demonstrated that the 
presence of allosteric agonist activity of mGlu5 PAMs can result in severe behavioral 
convulsions in rodents (67).  
We now report a series of studies in which we characterize two M1 PAMs that 
exhibit robust M1 agonist activity (MK-7622 and PF-06764427) and two structurally 
distinct M1 PAMs, VU0453595 (52) and VU0550164, that are devoid of agonist activity in 
cell lines. We then evaluate the physiological effects of PAMs with and without agonist 
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activity in the medial PFC (mPFC), a brain region important in cognition, and the potential 
cognitive and pro-convulsive effects in awake healthy rodents. 
MK-7622 and PF-06764427 display robust agonist activity in an in vitro calcium 
mobilization assay 
To assess the in vitro activity of the M1 PAMs used in this study, compounds were 
tested using Chinese Hamster Ovary (CHO) cells stably expressing the M1 receptor. The 
previously published M1 PAM PF-06764427 (55, 62) (Fig.1A, left) and Merck’s MK-7622 
(68) (Fig.1A, right) were evaluated for their ability to mobilize intracellular calcium (Ca2+) 
in the M1-CHO cells. The raw calcium traces (Fig. 1B) indicate that both PF-06764427 
and MK-7622 induce robust increases in Ca2+ mobilization in the absence of an 
orthosteric mAChR agonist. PF-06764427 alone causes a concentration-dependent 
increase in the mobilization of intracellular Ca2+ (Ago EC50 610 nM ± 14, Fig. 1C). 
Interestingly, we report a similar degree of intracellular Ca2+ mobilization with MK-7622 
alone (Ago EC50 2930 nM ± 95, Fig. 1D). Both PF-06764427 (PAM EC50 30 nM ± 3, Fig. 
1E) and MK-7622 (PAM EC50 16 nM ± 4, Fig. 1F) act as potent and selective (55) (Fig. 2) 
M1 PAMs in the presence of the orthosteric agonist ACh. Therefore, in addition to their 
PAM activity both PF-06764427 and MK-7622 have significant intrinsic agonist activity in 
this cell-based Ca2+ mobilization assay.  
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Figure 2: PF-06764427 and MK-7622 display robust intrinsic agonist activity in M1-
expressing CHO cells. 
Structures of the M1 PAMs PF-06764427 (left) and MK-7622 (right). (B) Representative 
raw calcium traces following the addition of 10 μM PF-06764427 (black), MK-7622 (light 
gray), and the subsequent additions of EC20 and EC80 concentrations of acetylcholine 
(ACh) (dotted line). (C) Agonist concentration-response curves of rM1-CHO calcium 
mobilization assay for PF-06764427 and (D) MK-7622 in the absence of ACh. (E) PAM 
concentration-response curves of rM1-CHO calcium mobilization assay for PF-06764427 
and (F) MK-7622 in the presence of an EC20 of ACh. Data represent mean ± S.E.M. from 
3 independent experiments performed in triplicate. 
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Figure 3: Selectivity of MK-7622 and VU0550164.  
Calcium mobilization assays were performed using CHO cells stably expressing M2-M5 
muscarinic receptors (M2 and M4 containing cells were co-transfected with Gqi5) to assess 
selectivity of MK-7622 and VU0550164. Neither MK-7622 (A) nor (B) VU0550164 exhibits 
any functional activity at the other rat muscarinic receptor subtypes. Data represent mean 
± S.E.M. from 3 independent experiments performed in triplicate. 
VU0453595 and VU0550164 act as highly selective PAMs lacking agonist activity 
in the M1 in vitro calcium mobilization assay 
 Previous studies suggest that over activation of the M1 mAChR can induce 
cholinergic adverse effects (62, 69). Based on these studies, we initiated an effort to 
optimize M1 PAMs that lack intrinsic agonist activity. We have previously reported 
characterization VU0453595 (52, 70) (Fig. 3A, left) and now disclose the novel M1 PAM 
VU0550164 (Fig. 3A, right). The raw Ca2+ traces (Fig. 3B) illustrate the lack of agonist 
activity of both VU0453595 and VU0550164 in the calcium mobilization assay even at 
high concentrations (>10 µM). As expected, VU0453595 had little to no effect on 
intracellular Ca2+ mobilization when applied alone (Fig. 3C). Similarly, the optimized M1 
PAM VU0550164 lacks agonist activity (Fig. 3D). However, both VU0453595 (PAM EC50 
2140 nM ± 436, Fig. 3E) and VU0550164 (PAM EC50 330 nM ± 44, Fig. 3F) can strongly 
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potentiate an EC20 concentration of ACh in a concentration-dependent manner. These 
data reveal that at concentrations significantly above the PAM EC50, VU0453595 and 
VU0550164 lack agonist activity in this assay, thereby demonstrating that these 
compounds are highly selective (52) (Fig. 2) PAMs devoid of agonist activity with respect 
to in vitro Ca2+ mobilization.  
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Figure 4: VU0453595 and VU0550164 lack significant agonist activity and are potent 
PAMs in M1 expressing CHO cells.  
(A) Structure of M1 PAM VU0453595 (left) and VU0550164 (right). (B) Representative 
raw calcium traces following the addition of 10 μM VU0453595 (black) and VU0550164 
(light gray) and the subsequent additions of EC20 and EC80 concentrations of 
acetylcholine (ACh) (dotted line). (C) Agonist concentration-response curves of rM1-CHO 
calcium mobilization assay for VU0453595 and (D) VU0550164 in the absence of ACh. 
(E) PAM concentration-response curves of rM1-CHO calcium mobilization assay for 
VU0453595 and (F) VU0550164 in the presence of an EC20 of ACh. Data represent mean 
± S.E.M. from 3 independent experiments performed in triplicate. 
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Ago-PAMs but not PAMs lacking agonist activity increase sEPSC in layer V 
mPFC pyramidal neurons  
To test whether PAMs displaying agonist activity in cell-based assays would have 
agonist activity in a native system, we evaluated the various M1 PAMs in a series of whole 
cell electrophysiology experiments in native brain tissue. Previously, we reported that 
activation of M1 can dramatically increase the activity of excitatory synaptic inputs onto 
layer V pyramidal cells in acute mPFC-containing brain slices (46). We now report that 
bath application of M1 ago-PAM PF-06764427 (1 µM) induces a marked increase in 
frequency of spontaneous excitatory post synaptic currents (sEPSCs) in mPFC layer V 
pyramidal cells (Fig. 4A, paired t-test, p < 0.05).  In addition, the second M1 ago-PAM, 
MK-7622 (1 µM), also increased sEPSC frequency (Fig. 4B, paired t-test, p <0.05). 
However, neither 10 µM VU0453595 (Fig. 4C) nor 10 µM VU0550164 (Fig. 4D) caused 
any significant change in sEPSC frequency (paired t-test, p > 0.05) at concentrations well 
above those required for maximal PAM activity. These results show that MK-7622 and 
PF-06764427 but not VU0453595 or VU0550164 have agonist activity in this native 
cortical preparation. 
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Figure 5: Ago-PAMs, but not PAMs devoid of agonist activity increase sEPSC 
frequency in layer V mPFC neurons.  
(A) Whole-cell recordings from pyramidal neurons (regular spiking firing) clamped at −70 
mV were performed in layer V of the prelimbic prefrontal mouse cortex. A sample trace 
of baseline (upper-trace) and during drug add (bottom-trace) and the cumulative 
probability of interevent intervals for a typical cell are shown in the (middle) during 
baseline and drug-add. Histogram summarizing the change in frequency of baseline to 
the drug peak effect (lower). Similar to 1 µM PF-06764427, bath application of 1 µM MK-
7622 (B) produced a statistically significant increase in sEPSC frequency, in contrast to 
bath application of (C) 10 µM VU0453595 and (D) 10 µM VU0550164 which induced no 
significant change in sEPSC frequency. Scale bars denote 50pA and 10 seconds.  
*p<0.05, paired t-test. 
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Ago-PAMs but not PAMs lacking agonist activity induce robust depression of 
fEPSP slopes in the mPFC  
We next tested the various M1 PAMs in a more circuit-level brain slice 
electrophysiology assay by measuring changes in layer V field excitatory post synaptic 
potentials (fEPSPs) evoked by electrical stimulation of afferents in layer II/III of the mPFC. 
Previously, we and others found that cholinergic agonists can induce an M1-dependent 
long-term depression (LTD) of fEPSP slope at this synapse (52, 53, 71). Consistent with 
the effects on sEPSCs, bath application of 1 µM PF-06764427 (Fig. 5A) induces a 
significant LTD of fEPSP slope 46-50 min (shaded area) after drug washout compared to 
baseline (paired t-test, p<0.05, Fig. 4B); this effect was absent in the presence of the 
selective M1 antagonist VU0255035 (72) (Fig. 6A) as well as in M1-KO mice (Fig. 6B). 
Quantification of LTD measured at 46-50 min after drug washout (shaded area) indicates 
a significant difference in the magnitude of LTD observed with application of 1 µM PF-
06764427 + 10 µM VU0255035 as well as 1 µM PF-06764427 in M1-KO mice compared 
to 1 µM PF-06764427 alone. (Fig. 6C) (one-way ANOVA, p<0.05). 
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Figure 6: Ago-PAMs, but not PAMs devoid of agonist activity robustly depress 
fEPSP slopes recorded in layer V of the prelimbic mPFC evoked by electrical 
stimulation in layer II/III  
(A) Time course graph showing that bath application of 1 µM PF-06764427 for 20 min 
leads to a robust long term depression (LTD) of fEPSP slope (B) Quantification of fEPSP 
slope 46-50 min following drug washout (shaded area) indicates a significant depression 
of fEPSP slope. n=9 brain slice experiments. *denotes p<0.05, paired t-test. (C) Under 
similar conditions bath application of 1 µM MK-7622 for 20 min led to an acute depression 
followed by a LTD of fEPSPs measured 46-50 min following drug washout. (D) 
Quantification of fEPSP slope 46-50 min following drug washout (shaded area) indicates 
a significant depression of fEPSP slope. n=9 brain slice experiments. ***denotes p<0.001, 
paired t-test. (E) Time course graph showing that bath application of 10 µM VU0453595 
for 20 min led to no significant change in fEPSP slopes (F) measured 46-50 min following 
drug washout. n=4 brain slice experiments. p>0.05, paired t-test. (G) Similar to 
VU04553595, 10 µM VU0550164 failed to induce any significant change in fEPSP 46-50 
min following drug washout (H). n=7 brain slice recordings, p<0.05. paired t-test. Time 
course data are expressed as mean ± S.E.M. Insert contains fEPSP sample traces during 
baseline (red) and 46-50 min following drug washout (black). Scale bar denotes 0.5 mV 
and 5 ms. 
 
 23 
Similarly, bath application of 1 µM MK-7622 for 20 minutes (Fig. 5C) induces a 
robust and statistically significant LTD measured at 46-50 min following drug washout 
(paired t-test, p<0.001) (Fig. 5D). This LTD was absent in the presence of VU0255035 
(Fig. 6D) as well as in brain slices obtained from M1-KO mice (Fig. 6E). Quantification of 
LTD (normalized fEPSP slopes) 46-50 min after drug washout (shaded area) indicates a 
significant difference in the magnitude of LTD observed with application of 1 µM MK-7622 
+ 10 µM VU0255035 as well as 1 µM MK-7622 in M1-KO mice compared to 1 µM MK-
7622 alone (one-way ANOVA, p<0.01) (Fig. 6F). 
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Figure 7: M1 Ago-PAM LTD in the mPFC is M1-dependent.  
Time course graph showing that bath application of 1 µM PF-06764427 fails to induce 
LTD in the presence of (A) 10 µM VU0255035, a highly selective M1 antagonist, and in 
(B) brain slices from M1-KO brain mice. Insert contains fEPSP sample traces during 
baseline (red) and 46-50 min following drug washout (black). (C) Quantification of LTD 
(normalized fEPSP slopes) 46-50 min after drug washout (shaded area) of the different 
experimental groups. There was a significant difference in the magnitude of LTD 
observed with application of 1 µM PF-06764427 + 10 µM VU0255035, as well as 1 µM 
PF-06764427 in M1-KO mice, compared to 1 µM PF-06764427 alone. One-way ANOVA 
was carried out with Dunnett’s post-hoc test, 1 µM PF-06764427 (white bar) as the control 
group. * p < 0.05. Under similar conditions bath application of 1 µM MK-7622 failed to 
induce LTD in the presence of (D) 10 µM VU0255035. (E) Correspondingly, 1 µM MK-
7622 failed to induce LTD in M1-KO mice brain slices. Quantification of LTD (normalized 
fEPSP slopes) 46-50 min following drug washout (shaded area). (F) There was a 
significant difference in the magnitude of LTD observed with application of 1 µM MK-7622 
+ 10 µM VU0255035 as well as 1 µM MK-7622 in M1-KO mice compared to 1 µM MK-
7622 alone. Data are expressed as mean ± S.E.M. One-way ANOVA was carried out with 
Dunnett’s post-hoc test with 1 µM MK-7622 (white bar) as the control group. ** p < 0.01. 
Numbers in the bar graph denote number of individual brain slice experiments.  
In contrast to the effects of MK-7622 and PF-06764427, high concentrations of M1 
PAMs VU0453595 and VU0550164 induce no change in fEPSP slope. As illustrated in 
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Fig. 4E-F, bath application of 10 µM VU0453595, a concentration known to potentiate the 
LTD induced by a submaximal concentration of carbachol (CCh) (52), for 20 minutes did 
not significantly change fEPSP slope compared to baseline (p>0.05). Furthermore, the 
second M1 PAM devoid of agonist activity in vitro, VU0550164 (10 µM) did not significantly 
change fEPSP slope compared to baseline when bath applied alone (p>0.05) (Fig. 5G-
H), but potentiated the response to 10 µM CCh (Fig. 7A) and induced a robust LTD only 
in the presence of an orthosteric agonist (Fig. 7B). Quantification of LTD indicates a 
significant difference in the magnitude of LTD observed with co-application of 10 µM 
VU0550164 + 10 µM CCh compared to 10 µM alone (p<0.05) (Fig. 7C). Taken together, 
these data demonstrate that MK-7622 and PF-06764427 display strong intrinsic M1 
agonist activity in this cortical brain slice electrophysiological assay, in contrast to 
VU0453595 and VU0550164 which lack agonist activity and maintain activity-
dependence of M1 activation in these native brain tissue assays. 
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Figure 8: VU0550164 potentiates CCh-LTD in the mPFC.  
(A) Time course graph showing that bath application 10 µM CCh induces a submaximal 
LTD 46-50min after drug washout (shaded area). (B) 10 min pretreatment of the M1 PAM 
VU0550164 and 10 min co-application of VU0550164 is able to potentiate 10 µM CCh 
producing a maximal LTD 46-50min after drug washout. Insert contains fEPSP sample 
traces during baseline (red) and 46-50 min following drug washout (black). (C) Bar graph 
denoting quantification of LTD (normalized fEPSP slopes) of the different experimental 
groups. There was a significant difference in the magnitude of LTD observed with 
application of 10 µM CCh compared to 10 µM VU0550164 + 10 µM, but no significant 
difference between 10 µM CCh and 10 µM VU0550164 alone. One-way ANOVA was 
carried out with with Dunnett’s post-hoc test. 10 µM CCh (white bar) as the control group. 
* p < 0.05.  Numbers in the bar graph denote number of individual brain slice experiments. 
Scale bar denotes 0.5 mV and 5 ms. 
MK-7622, but not VU0453595, induces behavioral convulsions in rodents  
In light of our finding that both PF-06764427 and MK-7622 have robust allosteric 
agonist activity in both cell line and native tissue assays, we hypothesized that MK-7622 
would induce behavioral convulsions in a manner similar to those observed with PF-
06764427 (62). Therefore, we performed a dose-escalation study in mice to assess 
seizure liability of the M1 ago-PAM MK-7622. Consistent with our previous study with PF-
06764427, 30 mg/kg and 100 mg/kg MK-7622 induces robust convulsions that reached 
stage 5 on the modified Racine scale (62, 67, 73) in WT but not in M1 KO mice (Fig. 8A). 
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While the M1 PAM VU0550164 does not have suitable pharmacokinetic properties for 
systemic administration, VU0453595 has excellent properties for use in in vivo studies 
(52).  Interestingly, VU0453595 induces no gross changes in behavior even at doses up 
to 100 mg/kg (Fig. 8A), well above doses that enhance cognition in rodents (52). 
Collectively, these findings suggest that M1 ago-PAMs, such as MK-7622 and PF-
06764427, induce behavioral convulsions that are not observed with PAMs lacking 
agonist activity such as VU0453595. 
VU0453595 but not MK-7622 can enhance rodent object recognition  
While M1 ago-PAMs such as MK-7622 and PF-06764427 do not induce overt 
seizures at lower doses, it is possible that over activation of M1 with ago-PAMs such as 
MK-7622 and PF-06764427 could disrupt cortical function and reduce efficacy of these 
compounds in enhancing cognitive function. Therefore, we performed a series of studies 
to evaluate the effects of the M1 ago-PAM MK-7622 and the PAM VU0453595 in an 
established model of recognition memory in healthy adult rats (Fig. 8B). Rats were chosen 
for these studies because they do not display overt behavioral convulsions in response 
to administration of M1 ago-PAMs and, for these studies, we used doses below those 
shown to induce behavioral convulsions in mice.  
 Interestingly, MK-7622 (1, and 3, and 10 mg/kg), did not significantly improve 
performance in the novel object recognition task (p=0.9110, one-way ANOVA) (Fig. 8C). 
In contrast, VU0453595, which lacks agonist activity induces a robust improvement in 
recognition memory in healthy adult rats assessed using the novel object recognition task. 
At 1, 3, and 10 mg/kg, VU0453595 enhances object recognition as indicated by a 
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significant increase in the recognition index (Dunnett’s multiple comparison test: 
p=0.0008) (Fig. 8D).  
 
Figure 9: MK-7622 induces robust behavioral convulsions and lacks efficacy in 
enhancing rodent cognition.  
(A) C57Bl6/j mice were administered 3, 10, 30, 100 mg/kg MK-7622, and behavioral 
convulsions were measured for 3 h using the modified Racine scale (0−5). M1-KO mice 
exhibit no behavioral convulsions, suggesting that MK-7622 induces behavioral 
convulsions in a M1-dependent fashion. Compounds were formulated in 10% Tween 80 
and delivered intraperitoneally. Data represent mean ± SEM (n = 3 mice per dose). This 
is in contrast to VU0453595, which displays no overt adverse effects at concentrations 
up to 100 mg/kg (n = 3 mice). (B) Schematic of the rodent Novel Object Recognition 
paradigm. (C) Pretreatment with 1, 3, and 10 mg/kg of 90min before the familiar phase 
failed to significantly enhance object recognition assessed 24 hr later. (p=0.9110, n=11-
12 rats per group). (D) Under similar conditions for MK-7622, VU0453595 dose-
dependently enhances object recognition in rats. Pretreatment with 1, 3, and 10 mg/kg 
90 min before the familiar phase enhanced object recognition memory assessed 24 hr 
later (p=0.008, n=11-12 rats per group). Data are expressed as mean ± SEM. *p< 0.05.   
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These studies suggest that the ability of MK-7622 to activate M1 mAChRs 
regardless of presynaptic acetylcholine release may lead to aberrant receptor activity and 
may even disruption cognition and could therefore explain why MK-7622 did not meet 
clinical endpoints in an proof-of-concept clinical trial in AD patients (74). Together, these 
studies provided fundamental new insights into the impact of subtle differences in modes 
of activity of different M1 PAMs and the need to strictly avoid allosteric agonist activity in 
these compounds. 
 
Agonist activity is dependent in part on receptor reserve 
Characterization of M1 PAM PF-06827443 
In opposition to this hypothesis, the newer PF-06827443 was previously 
demonstrated to display minimal agonist activity in cell lines expressing human M1 but 
induced severe adverse effects in some preclinical animal models (34). One way to 
account for this finding is that agonist activity can vary dramatically depending on total 
receptor expression, known conceptually as receptor reserve. This is the concept that a 
full pharmacological response can be induced at ligand concentrations that do not 
saturate the receptor (75). Therefore, an allosteric modulator in systems with low receptor 
expression (low receptor reserve) may display partial agonism or no agonist activity at all. 
However, when the same ligand is tested in a cell line or system with high receptor 
expression (high receptor reserve), it may unmask agonist activity not seen in low 
expression systems. Therefore, we hypothesized that using cell lines with varied levels 
of M1 receptor reserve, we could reveal agonist activity of PF-06827443. 
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In order to test this hypothesis, we first evaluated the ability of PF-06827443 to 
directly activate M1 as assessed by mobilization of intracellular calcium (Ca2+) in Chinese 
Hamster Ovary (CHO) cells stably expressing the rat M1 receptor. PF-06827443 induces 
a robust increase in intracellular Ca2+ in the absence of an orthosteric mACh receptor 
agonist (rat ago EC50 1900 nM; 81 ± 5% ACh Max, Figure 9) and is a potent PAM in the 
presence of an EC20 concentration of acetylcholine (rat PAM EC50 36.1 ± 4.9 nM; 97 ± 
1% ACh Max, Figure 9B). Additionally, PF-06827443 displays similar agonist and PAM 
activities at the dog and human M1 receptors (Figure 10). Furthermore, unlike other M1 
PAMs devoid of agonist activity, PF-06827443 inhibits [3H]-NMS binding, which likely 
reflects negative cooperativity with antagonist binding at the orthosteric binding site 
(Figure 11).  
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Figure 10: PF-06827443 displays intrinsic agonist activity in rM1-CHO cells with 
high receptor expression.  
(A) Representative raw calcium traces following the addition of 30 μM PF-06827443 
(black) and the subsequent additions of EC20 and EC80 concentrations of acetylcholine 
(ACh) (dotted line). (B) Concentration-response curves (CRC) of rM1-CHO calcium 
mobilization assay for PF-06827443 in the absence of ACh (Agonist Mode; Black) and 
the presence of an EC20 of ACh (PAM Mode; Red). Concentration-response curves for 
(C) PF-06827443 and (D) VU0550164, in the absence of ACh, in cell lines treated with 5 
ng, 15 ng, 25 ng, and 1 μg of tetracycline as well as rM1 CHO cells. Data represent mean 
± S.E.M. from 3 independent experiments performed in triplicate. 
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Figure 11: PF-06827443 displays intrinsic agonist activity in M1-expressing CHO 
cells, independent of species.  
(A) PF-06827443 concentration-response curves (CRC) of calcium mobilization assay in 
CHO cells stably expressing the dog M1 receptor in the absence of ACh (Agonist Mode; 
Black) and the presence of an EC20 of ACh (PAM Mode; Red). (B) Under similar 
conditions, concentration response curves were generated for PF-06827443 in CHO cells 
stably expressing the human M1 receptor. Data represent mean ± S.E.M. from 3 
independent experiments performed in triplicate. 
 
Figure 12: PF-06827443 displaces [3H]-NMS at rat M1 receptors.  
(A) Inhibition of orthosteric radioligand binding with [3H]-NMS by PF-06827443 and 
atropine control. Data are plotted as a percentage of specific [3H]-NMS binding. Data 
represent the mean ± SEM from three separate experiments performed in triplicate. 
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 While PF-06827443 was previously demonstrated to have minimal agonist activity 
at human M1 (34), this discrepancy could due to the use of a cell line with lower M1 
expression as agonist activity of GPCR PAMs is dependent on receptor expression levels 
(67, 76–79). To determine whether the robust agonist activity is dependent on levels of 
receptor expression, we used a TREx-CHO cell line in which the rM1 receptor is under 
control of the tetracycline (TET) repressor protein, enabling us to systematically increase 
M1 expression by adding increasing amounts of TET. This permits the measurement of 
M1 activation in a single cellular background with different levels of receptor reserve. As 
shown in Table 1, increases in M1 receptor expression was observed in a TET-
concentration dependent manner and cells treated with 25ng/mL TET show comparable 
M1 expression levels as CHO cells stably expressing rM1 and hM1. Similarly, increasing 
concentrations of TET led to a progressive increase in M1 receptor expression, and a 
leftward shift in the ACh potency (Table 2).  PF-06827443 shows comparable agonist 
activity in the cells treated with 25 ng TET (ago EC50 = 2300 nM; 54 ± 5% ACh Max, 
Figure 9C) to one in rat M1-CHO. However, in cells with 1 µg TET, PF-06827443 exhibits 
robust agonist activity at high receptor expression levels (ago EC50 = 400 nM ; 78 ± 2% 
ACh Max), which is not as evident at lower expression levels, e.g. 5 ng and 15 ng TET 
(Figure 9C). In contrast, a previously characterized M1 PAM optimized to lack agonist 
activity, VU0550164, does not exhibit agonism at any receptor expression level (Figure 
9D). 
 
 
 34 
 
Rat M1-TREx CHO 
Bmax (fmol/mg) 
± SEM 
5 ng TET 48 ± 4 
15 ng TET 139 ± 8 
25 ng TET 1066 ± 27 
1000 ng TET 5859 ± 188 
rM1-CHO 1305 ± 208 
hM1-CHO 1479 ± 129 
 
Table 1: Receptor densities determined from saturation binding assay  
Data represents values determined from displacement of varying concentration of [3H]-
NMS ranging from 3nM to 0.003 nM) using the cell membranes isolated from rat M1-TREx 
CHO that induced with different TET amount compared to the CHO cells stably 
expressing rM1 and hM1 receptors. Values represent the mean ± SEM of two experiments 
performed in triplicate.  
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Condition 
ACh concentration 
(nM)  
(± SEM) 
EC20  
% response 
5 ng TET 45.3 + 1.3 16 + 2 
15 ng TET 19.3 + 1.3 16 + 1 
25 ng TET 1.4 + 0.2 15 + 1 
1 ug TET 0.2 + 0.0 13 + 1 
rM1-CHO 1.2 + 0.0 14 + 1 
 
Table 2: Comparison of acetylcholine concentration to elicit EC20 response in each 
TET condition in rat M1 TREx-CHO and rat M1-CHO.   
There is a leftward shift of ACh potency with increasing amount of TET.  Incubation with 
25 ng TET shows comparable ACh potency to one in rat M1-CHO.a Data values 
determined from ACh concentration necessary to elicit a ~EC20 % response in the various 
cell lines. Values represent the mean ± SEM of three independent experiments performed 
in triplicate. 
PF-06827443 displays robust agonist activity in the mPFC 
Native systems often have a high receptor reserve for M1 (76, 78); thus, it is 
important to evaluate the potential agonist activity of PF-06827443 in a native system 
relevant to rodent cognition. Previously, we and others found that cholinergic agonists, as 
well as M1 ago-PAMs, can induce an M1-dependent long-term depression (LTD) of layer 
V field excitatory post synaptic potentials (fEPSPs) electrically evoked by stimulation of 
layer II/III in the mouse PFC (Figure 12A) (52, 53, 57, 71). Therefore, we tested the 
hypothesis that PF-06827443 would induce an LTD of fEPSPs at this cortical synapse 
similar to previously described ago-PAMs (57). Consistent with previous studies, 1 µM 
 36 
(77.8 ± 4.27%, Figure 12B) and 10 µM PF-06827443 (51.8 ± 3.78%, Figure 12C) induce 
a sustained LTD of fEPSPs in the PFC. This effect of PF-06827443 was completely 
blocked by the highly selective M1 antagonist VU0255035 (72), confirming that this PF-
06827443 induced-LTD is M1-dependent (101.6 ± 9.30%, Figure 12D). Quantification of 
LTD measured at 46-50 min after drug washout (shaded area) indicates a significant 
difference in the magnitude of LTD observed with application of 1 µM PF-06827443 + 10 
µM VU0255035 compared to 1 µM PF-06827443 alone (Figure 12E, one-way ANOVA, 
p<0.05). Therefore, similar to other M1 ago-PAMs, PF-06827443 displays robust agonist 
activity in the mouse PFC, a brain region heavily implicated in cognition. 
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Figure 13: PF-06827443 robustly depresses fEPSP slopes recorded in layer V of the 
prelimbic mPFC evoked by electrical stimulation in layer II/III.  
(A) Schematic the fEPSPs recorded from layer V of the mouse PFC in response to 
electrical stimulation in the superficial layers II–III. Time-course graph showing that bath 
application of (B) 1 µM PF-06827443 and (C) 10 µM PF-06827443 for 20 min leads to a 
robust long-term depression (LTD) of fEPSP slope. (D) Time course graph showing that 
bath application of 1 µM PF-06827443 fails to induce LTD in the presence of 10 µM 
VU0255035, a highly selective M1 antagonist. Insert contains fEPSP sample traces during 
baseline (red) and 46-50 min following drug washout (black). Scale bars denote 0.2 mV 
and 5 seconds. n=6-8 brain slice experiments per group. (E) Quantification of LTD 
(normalized fEPSP slopes) 46-50 min after drug washout (shaded area) of the different 
experimental groups. There was a significant difference in the magnitude of LTD 
observed with application of 1 µM PF-06827443 + 10 µM VU0255035 compared to 1 µM 
PF-06827443 alone. One-way ANOVA was carried out with Dunnett’s post-hoc test, 1 µM 
PF-06827443 (black bar) as the control group. * p < 0.05.  
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PF-06827443 increases sEPSC frequency in layer V prelimbic mPFC neurons 
  In addition, we performed studies to test the hypothesis that bath application of 
PF-06827443 would increase the frequency of spontaneous excitatory postsynaptic 
currents (sEPSCs) measured in layer V pyramidal cells of the PFC (Figure 13A) similar 
to previously characterized M1 ago-PAMs (57). In agreement with previous studies, 10 
µM PF-06827443 decreases the inter-event-interval (IEI) (Figure 13B) and consequently, 
significantly increases sEPSC frequency in layer V pyramidal cells (Figure 13C, paired t-
test, p<0.05). Together, these results show that PF-06827443 displays robust agonist 
activity in two native tissue electrophysiological assays.  
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Figure 14: PF-06827443 increases sEPSC frequency in layer V prelimbic mPFC 
neurons.  
(A) Whole-cell recordings from pyramidal neurons (regular spiking firing) clamped at −70 
mV were performed in layer V of the prelimbic prefrontal mouse cortex. A sample trace 
of baseline (upper-trace) and during drug add (bottom-trace) for a typical cell are shown. 
Scale bars denote 50 pA and 2 seconds. (B) Histogram summarizing the change in the 
inter-event-interval of baseline (black) to the drug peak effect (grey). (C) 10 µM PF-
06827443 produced a statistically significant increase in sEPSC frequency. n=8 slices. 
Student’s t-Test; * p < 0.05. 
PF-06827443 induces behavioral convulsions in mice 
As seen with other ago-PAMs (57, 62), we hypothesized that this overactivation of 
M1 by PF-06827443 in native brain tissue preparations is responsible for M1-induced 
behavioral convulsions. We next tested the hypothesis that the agonist activity of PF-
06827443 seen in in vitro and native tissue assays would correlate to behavioral 
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convulsions when administered in mice. Therefore, we performed a single high dose (100 
mg/kg) PF-06827443 study in M1 knockout (KO) mice and littermate controls to assess 
seizure liability. Consistent with our previous ago-PAM studies, 100 mg/kg PF-06827443 
induced behavioral convulsions that reached stage 3 on the modified Racine scale (62, 
73) in  wildtype littermate mice that were absent in M1 KO mice (Figure 14). Collectively, 
these findings demonstrate that high doses of PF-06827443 induce behavioral 
convulsions in mice similar to the adverse effects previously published in dogs (34).  
 
Figure 15: PF-06827443 induces behavioral convulsions in mice.  
(A) C57Bl6/J mice were administered a single 100 mg/kg dose of PF-06827443 and 
behavioral convulsions were measured for 3 h using the modified Racine scale (0−5). M1-
KO mice treated with PF-06827443 exhibit no behavioral convulsions, suggesting that 
PF-06827443 induces behavioral convulsions in an M1-dependent fashion. Compounds 
were formulated in 10% Tween 80 and delivered intraperitoneally. Data represent mean 
± SEM (n = 3 mice per dose). 
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Discussion 
Overactivation of the M1 mAChR may be detrimental to M1 PAM efficacy 
Over the last decade, multiple M1 PAMs have demonstrated robust efficacy in 
reversing cognitive disruptions in preclinical animal models relevant for AD (41, 51, 80) 
and schizophrenia (48, 49, 52, 53, 81, 82). While these findings are very promising, recent 
studies have revealed that some but not all M1 PAMs display adverse effects including GI 
distress and behavioral convulsions in rodents and dogs (34, 57, 62). Previously, it was 
demonstrated that the nonselective muscarinic orthosteric agonist pilocarpine induced 
robust seizures in healthy adult mice and mice in which M2, M3, M4 or M5 was genetically 
knocked out (KO) but produced no effect in M1-KO mice, suggesting that overactivation 
of the M1 receptor mediates these adverse effects (63, 64). Therefore, one possibility to 
account for the stark contrast between M1 PAMs that produce adverse effects and those 
that do not is the hypothesis that some M1 PAMs can overactivate the M1 receptor and 
therefore lead to similar adverse effects as traditional orthosteric agonists (57, 62, 65, 
66). This is reminiscent of studies from allosteric modulators for other GPCRs, such as 
the metabotropic glutamate receptor subtype 5 (mGlu5), which demonstrated that the 
presence of allosteric agonist activity of mGlu5 PAMs can results severe behavioral 
convulsions in rodents (67, 73).  
In agreement with this hypothesis, M1 PAMs such PF-06764427 and MK-7622 
demonstrate robust agonist activity in addition to PAM activity (ago-PAM) and when 
dosed at high concentrations display M1-dependent behavioral convulsions in rodents 
(57, 62). This contrasts with two structurally distinct M1 PAMs, VU0453595 and 
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VU0550164, optimized to eliminate agonist activity (57). Similar to previously described 
M1 PAMs, VU0453595 and VU0550164 robustly potentiate responses to ACh (57). 
However, in contrast with PF-06764427 and MK-7622, VU0453595 and VU0550164 lack 
agonist activity in all assays tested (57). Furthermore, both PF-06764427 and MK-7622 
induce robust behavioral convulsions in adult mice that were absent in M1-KO mice, 
suggesting that overactivation of M1 is responsible for the ago-PAM-induced behavioral 
convulsions (57). These severe adverse effects were not present at any concentration of  
VU0453595, an M1 PAM optimized to avoid allosteric agonist activity (57). Finally, 
VU0453595, but not MK-7622, exhibited robust efficacy in improving object recognition 
memory in rats (57). Together, these studies greatly expand our knowledge into the 
impact of subtle differences in modes of activity of different M1 PAMs and the need to 
strictly avoid allosteric agonist activity in these compounds. 
 In opposition to the hypothesis that agonist activity is a strong contributor of 
adverse effect liability was the disclosure of PF-06827443, a highly selective and potent 
M1 PAM with weak agonist activity at the human M1 receptor but which induces severe 
seizures when administered to dogs (34). Based on the relatively weak agonist activity of 
PF-06827443, the authors suggested that severe adverse effect liability is not dependent 
on agonist activity of M1 PAMs.  However, this study relied on a single cell line expressing 
the human M1 mAChR, and PF-06827443 was not extensively characterized to establish 
the level of agonist activity of this M1 PAM in other preclinical systems.  Allosteric agonist 
activity is highly dependent on receptor expression levels (67, 79) and there are 
documented species differences in the pharmacological profiles for other muscarinic 
allosteric modulators (83, 84). Since animal models, such as rodent, dog and monkey, 
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often drive preclinical drug discovery, it is therefore critical to fully assess agonist activity 
across different levels of receptor expression, in different species, and in native systems 
to fully evaluate intrinsic agonist activity of M1 PAMs.  
 In contrast to their molecular pharmacology findings, we found that PF-06827443 
displays robust agonist activity across cell lines expressing rat, dog and human M1 (66). 
Furthermore, we used an inducible cell line to control M1 receptor expression and found 
that PF-06827443 displays agonist activity in systems with moderate to high receptor 
reserve (66). In contrast, VU0550164, an M1 PAM optimized to avoid ago-PAM activity 
(57) exhibits no agonist activity at any expression level tested. Finally, unlike recently 
reported M1 PAMs optimized to eliminate agonist activity (57), PF-06827443 displays 
robust agonist activity in mouse brain slices and induces behavioral convulsions in mice 
that is similar to other previously described ago-PAMs (e.g. MK-7622 and PF-06764427). 
Taken together, these findings reveal that PF-06827443 is a robust M1 ago-PAM and add 
further support to the hypothesis that intrinsic agonist activity may be a detrimental quality 
for M1 PAM clinical candidates.  
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CHAPTER 3  
MULTIPLE MODES OF PAM ACTIVITY 
M1 PAMs that display bias can have differential effects in the CNS 
In addition to differences in allosteric agonist activity, M1 PAMs can also differ in 
their ability to confer bias to M1 signaling. Signal bias is the phenomenon by which 
different GPCR ligands induce distinct active receptor-complex states that are biased 
toward or away from specific signaling pathways (Fig. 15) (85). To date, GPCR signal 
bias has been well characterized for µ opioid agonists that can signal through G-proteins 
as well as β-arrestin or both (86, 87). Recent work suggests that µ opioid agonists that 
avoid β-arrestin activity and preferentially signal through G-proteins can induce analgesia 
while minimizing respiratory suppression. Recent work suggests that µ opioid receptor 
agonists that avoid β-arrestin activity and preferentially signal through G-proteins can 
induce analgesia while minimizing respiratory suppression. Therefore, these biased 
ligands could provide a larger therapeutic window than fentanyl, which preferentially 
signals through β-arrestin and produces robust respiratory depression (88, 89). Thus, 
characterization of potential signal bias in muscarinic ligands may provide opportunities 
to understand specific signaling pathways involved in efficacy and potentially increase in 
vivo efficacy while minimizing adverse effect liability.  
Characterization of a broad range of structurally diverse M1 PAMs revealed that 
some M1 PAMs confer signal bias and potentiate receptor signaling through the canonical 
phospholipase C (PLC) pathway, but do not potentiate M1 receptor–mediated activation 
of phospholipase D (PLD) (90). PLD is a widely expressed enzyme that hydrolyzes the 
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major plasma membrane phospholipid phosphatidylcholine into the signaling molecules 
phosphatidic acid (PA) and choline (91). PLD can be activated by various receptors, 
including the M1 receptor (92, 93). Although there are six distinct mammalian isoforms of 
PLD, only PLD1 and PLD2 have well-established enzymatic activity within the central 
nervous system (CNS) (91, 94).  
However, little is known about the roles of PLD in regulating brain function, and the 
potential roles of PLD in M1 receptor–dependent signaling has not been explored. Thus, 
it is unclear whether M1 receptor PAMs that do not activate coupling of the receptor to 
PLD in cell lines will display functional differences in regulating M1 signaling in the CNS 
relative to nonbiased M1 receptor PAMs. For other GPCRs, signal bias provides the 
exciting potential advantage of selectively activating or potentiating therapeutically 
relevant pathways while minimizing activation of pathways responsible for adverse effects 
(39, 88, 95). Therefore, a better understanding of these signaling mechanisms is essential 
for the development of M1 receptor PAMs as potential therapeutics for the treatment of 
prevalent cognitive disorders. 
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Figure 16: Biased M1 PAM schematic.  
(A) Cartoon depicting the effect of biased or nonbiased M1 PAMs on mAChR signaling. 
(B) Simplified signaling cascade downstream of the M1 mAChR involving both PLC and 
PLD.  
Here, we report that PLD activity is necessary for a form of M1 receptor–dependent 
long-term depression (LTD) in the prefrontal cortex (PFC), which was previously 
implicated in the potential therapeutic response to M1 receptor PAMs (52, 53, 96). 
Furthermore, biased M1 PAMs that do not potentiate M1 receptor coupling to PLD failed 
to potentiate this form of LTD, but actively inhibited M1 receptor–dependent LTD at this 
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synapse. In contrast, biased and nonbiased M1 receptor PAMs functioned similarly in their 
ability to potentiate M1 receptor–dependent responses in the CNS that we found to be 
PLD-independent. Together, these studies reveal that PLD is a critical downstream 
signaling node for this M1 receptor–dependent LTD in the PFC and demonstrate that 
biased M1 receptor PAMs can have fundamentally different effects, relative to those of 
nonbiased M1 receptor PAMs, in regulating specific aspects of CNS function.   
M1 receptor activation leads to PLD activity in hM1-CHO cells 
 M1 receptor activation leads to an increase in PLD activity (92, 93), but it is not 
known whether this reflects activation of PLD1, PLD2, or both isoforms. Therefore, we 
characterized the relative contribution of these two distinct PLD isoforms downstream of 
selective activation of M1 in Chinese Hamster Ovary (CHO) cells stably expressing the 
M1 receptor. Whereas direct measurement of the PLD product PA is challenging due to 
its rapid conversion into other lipids, such as diacylglycerol and lysophosphatidic acid, in 
the presence of a primary alcohol, such as 1-butanol, PLD generates the stable product 
phosphatidylbutanol (pButanol), which cannot be metabolized, and enables quantification 
of intracellular PLD activity (91, 97, 98). Consistent with previous findings (90), the 
cholinergic orthosteric agonist carbachol (CCh) induced an increase in pButanol 
accumulation, which was blocked by the selective M1 receptor antagonist VU0255035 
(Fig. 16A) (72). Furthermore, the PLD1,2 inhibitor ML299 (99) blocked M1-mediated 
pButanol production, thereby supporting the hypothesis that PLD was responsible for the 
generation of pButanol. Using more modern PLD1 (VU0359595) (100) and PLD2 
(VU0364739) (101) isoform-selective inhibitors, we found that pharmacological inhibition 
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of PLD1, but not PLD2, blocked the M1-dependent activation of PLD in this in vitro assay 
(Fig. 16A). These data suggest that in this cell-based assay, M1-dependent activation of 
PLD primarily occurs through PLD1, not PLD2. 
 Although we have previously characterized M1 PAMs that couple to PLC but not 
PLD (90), these early biased M1 PAMs suffered from low potency and aqueous solubility. 
Therefore, we optomized additional M1 PAMs that potentiate M1 coupling to PLC, but do 
not potentiate coupling to PLD. Previously, we reported that the M1 PAMs VU0453595 ( 
(EC50) = 2140 ± 440 nM),  VU0405652 (EC50 = 2580 ± 440 nM), and VU0405645 (EC50 
= 340 ± 30 nM) are potent M1 PAMs with respect to their ability to potentiate Ca2+ 
mobilization in CHO cells stably expressing the M1 receptor (Fig. 16, B and C) (52, 102). 
We now report that unlike the prototypical M1 PAM VU0453595, both VU0405652 and 
VU0405645 failed to potentiate the CCh-dependent activation of PLD in this in vitro assay 
(Fig. 16D). These findings demonstrate that VU0405652 and VU0405645, but not 
VU0453595, are biased M1 receptor PAMs that do not potentiate M1 coupling to PLD. 
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Figure 17: M1 receptor activation leads to PLD activity in hM1-CHO cells, and M1 
PAMs show differential signal bias in potentiating M1-mediated PLD signaling.  
(A) rM1 CHO cells were treated with DMSO (basal) or 100 M CCh alone or in 
combination with 2 µM VU0255035 (M1 antagonist), 2 µM ML299 (PLD1,2 inhibitor), 1 µM 
VU0359595 (PLD1 inhibitor), or 750 nM VU0364739 (PLD2 inhibitor). PLD activity was 
measured by quantification of the PLD product pButanol. The extent of PLD activity in 
response to 100 µM CCh alone was set at 100%. The effects of the M1 receptor antagonist 
or various pharmacological inhibitors of PLD were compared to the maximal effect elicited 
by 100 M CCh (one-way ANOVA F4,10 = 29.34 ; P = 0.0001, with a post-hoc Dunnett’s 
test using 100 M CCh alone as the control group, ***P < 0.001). (B) Structures of the M1 
receptor PAMs VU0453595, VU0405652, and VU0405645. (C) rM1-CHO cells were 
treated with an EC20 concentration of acetylcholine in the presence of the indicated 
concentrations of VU0453595, VU0405652, and VU0405645 and then were assayed for 
Ca2+ signaling by using the Functional Drug Screening System (FDSS7000). (D) Using 
rM1 CHO cells under the same conditions described above, the extent of PLD activation 
relative to a maximal response of 100 µM CCh alone was evaluated for 4 µM CCh in the 
presence of DMSO, 10 µM VU0453595, 10 µM VU0405652, or 10 µM VU0405645 (one-
way ANOVA F3,8 = 55.1; P = 0.0001, with a post-hoc Dunnett’s test using 4 M CCh *P < 
0.05, **P < 0.01, ***P < 0.001). Data in (A), (C), and (D) are means ± SEM from three 
independent experiments each performed in triplicate. 
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PLD1, but not PLD2, is required for M1 receptor–mediated LTD in the mPFC 
 While these cell-based studies demonstrated that M1 receptor activation can 
increase PLD activity, little is known about whether PLD is necessary for M1-dependent 
responses in native neuronal tissue. Therefore, we characterized the role of PLD in 
mediating established responses to M1 receptor activation in CNS preparations. One 
response to M1 receptor activation that may be relevant to some aspects of cognitive 
function is induction of long-term depression (LTD) of excitatory synaptic transmission in 
the medial prefrontal cortex (mPFC) (52, 53, 57, 65, 71, 96). We assessed the role of 
PLD in inducing LTD in the mPFC by measuring changes in layer V field excitatory 
postsynaptic potentials (fEPSP) evoked by electrical stimulation of afferents in layer II/III 
of the mPFC (Fig. 17A). Consistent with previous findings (52, 53, 65, 71), a maximal 
concentration of CCh induced robust LTD of fEPSP slope at this synapse (Fig. 17B). In 
order to test whether PLD is required for CCh-induced LTD, we bath applied the PLD1,2 
inhibitor ML299 for 10 min before and throughout CCh application which resulted in a 
complete loss of CCh-induced LTD (Fig. 17C). Using selective inhibitors for each PLD 
isoform, we found that pharmacological inhibition of PLD1 with VU0359595 fully blocked 
CCh-induced LTD (Fig 17D). Congruent with the cell-based assay findings, inhibition of 
PLD2 with VU0364739 had no effect on CCh-induced LTD at this synapse (Fig. 17E). 
Quantification of fEPSP slope 46–50 min following drug washout indicated that ML299 
and VU0359595 significantly attenuated CCh-induced LTD whereas inhibition of PLD2 
with VU0364739 had no significant effect (Fig. 17F). 
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Figure 18: PLD1 but not PLD2, is necessary for CCh-dependent LTD in the mPFC.  
(A) Schematic of the field excitatory post-synaptic potentials (fEPSP) recorded from layer 
V of the mouse mPFC in response to electrical stimulation in the superficial layers II–III. 
(B) Time course graph for fEPSP slope normalized to the average baseline. 50 μM 
carbachol (CCh) induces a long-term depression of fEPSP slope (68.0 ± 4.44%, n/N= 
26/20 slices/mice). (C) Time course graph for fEPSP slope with 10 min pretreatment of 
the PLD1,2 inhibitor ML299 (2 μM), followed by a 10 min co-application of ML299 and 50 
μM CCh (93.8 ± 6.74%, n/N= 21/10). (D) Time course graph for fEPSP slope normalized 
to baseline with 10 min pretreatment of the PLD1-specific inhibitor VU0359595 (370 nM) 
and 10 min co-application of 50 μM CCh (101 ± 10.1%, n/N= 7/6).  (E)  Time course graph 
for fEPSP slope normalized to baseline with 10 min pretreatment of the PLD2 selective 
inhibitor VU0364739 (750 nM) and 10 min co-application of 50 μM CCh (69.3 ± 13.0, n/N= 
8/4). Inset shows representative fEPSP traces for each condition for baseline (red trace) 
and 50 min after CCh washout (black trace). (F) Quantification of the average fEPSP 
slope 46–50 min following drug washout (shaded area) (one-way ANOVA F3,58 = 5.21; P 
= 0.0029, with a post-hoc Dunnett’s test using 50 μM CCh alone as the control group, *P 
< 0.05, **P < 0.01). (G) Left: Time course graph of fEPSP slope normalized to baseline 
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with bath application of CCh (100 μM) in littermate controls (59.6 ± 6.06 n/N= 9/6) and 
PLD1 KO mice (92.2 ± 3.21, n/N= 9/6). Right: representative fEPSP traces for baseline 
(red trace) and 50 min after CCh washout (black trace) for PLD1 KO animals (Top) and 
littermate controls (Bottom). (H) Quantification of the average fEPSP slope 46–50 min 
following drug washout (shaded area) (Student’s t-test; P = 0.0002, ***P < 0.001). (I)  
Time course graph for fEPSP slope normalized to baseline with 10 min bath application 
of group II metabotropic glutamate receptor agonist LY379268 (200 nM) in PLD1 KO mice 
(59.4 ± 11.4%, n/N = 5/3). (J) Quantification of the average fEPSP slope 46–50 min 
following LY379268 (200 nM) washout (shaded area) for PLD1 KO mice and littermate 
controls (55.7 ± 11.6%, n/N = 7/3; Student’s t-test; P = 0.828). Inset shows representative 
fEPSP traces for each condition for baseline (red trace) and 50 min after LY379268 
washout (black trace). Scale bars denote 0.25 mV and 5 ms. Data are expressed as mean 
± SEM. 
 To confirm these pharmacological results, we obtained PLD1 knockout (KO) mice 
and subsequently confirmed that PLD1 expression is reduced in cortical tissue compared 
to littermate controls (Fig. 18). In agreement with the pharmacological findings, CCh 
induced a robust LTD in slices obtained from littermate controls but not from PLD1 KO 
mice (Fig. 17G, H). Importantly, the ability of a selective agonist of group II metabotropic 
glutamate receptors (LY379268) to induce LTD was intact in the PLD1 KO mice and not 
significantly different than littermate controls (Fig. 17 I, J). This form of LTD has been 
previously characterized in detail and is mechanistically distinct from M1-dependent LTD 
in the mPFC (103–105). Furthermore, input-output curves generated by comparing fiber 
volley slope to fEPSP slope (Fig. 19A) did not appear to differ between genotypes (Fig. 
19B). These data together suggest that the loss of M1-mediated LTD is not due to a 
general deficit in LTD in this brain region. Taken together, these data demonstrate a 
critical role of PLD, specifically PLD1, in this form of cortical M1-LTD. 
 
 53 
 
Figure 19: Western blot validation of PLD1 KO mice.  
Total protein from cortex was probed with a PLD1 specific antibody (Cell Signaling 
Technology #3832). The immunoreactive band corresponding to PLD1 (~120 kDa) was 
absent in samples from KO mice.  
 
 
Figure 20: Input/output relationship of fEPSPs compared to fiber volley from PLD1 
KO mice and littermate controls.   
(A) Representative sample trace generated from electrical stimulation of layer II/II and 
recording in layer V of the mPFC. 1: corresponds to the fiber volley and 2: corresponds 
to the fEPSP. Scale bars denote 0.5mV and 5 ms.  (B) The fiber volley slope was plotted 
against fEPSP slope from PLD1 littermates (n=12/N=3 slices/mice, black) and PLD1 KO 
mice (n=10/N=2, red). Data are expressed as mean ± SEM. 
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Biased M1 receptor PAMs fail to potentiate M1 receptor–dependent LTD in the 
mPFC 
 We next tested the hypothesis that biased and non-biased M1 receptor PAMs 
would display functional differences in their ability to potentiate this PLD-dependent CCh-
induced LTD of layer V fEPSPs electrically evoked in layer II/III in the mPFC. As 
previously shown, a submaximal concentration of CCh (10 µM) does not induce LTD at 
this synapse (Fig. 20A) (52, 57, 65). Similar to previous findings, bath application of the 
non-biased M1 receptor PAM VU0453595 for 10 min before and during CCh application 
lead to a robust LTD (Fig. 20B).  Consistent with a role of PLD in inducing M1-LTD, neither 
of the biased M1 receptor PAMs, VU0405652 (Fig. 20C) nor VU0405645 (Fig. 20D), 
potentiated the LTD response to a submaximal concentration of CCh. Quantification of 
fEPSP slope following drug washout indicated a significant depression of fEPSP slope 
compared to baseline with the M1 receptor PAM VU0453595 but not VU0405652 nor 
VU0405645 (Fig. 20E). 
 Theoretically, M1 receptor PAMs that confer this form of biased M1 receptor 
signaling stabilize a conformation of M1 receptor that favors activation of signaling by PLC 
and not PLD (22, 85, 106, 107). If correct, these PAMs confer true bias to M1 signaling, 
and should inhibit PLD-mediated responses. Thus, we tested the hypothesis that PAMs 
that bias M1 receptor signaling away from PLD would block the LTD normally induced by 
a maximal concentration of CCh (Fig. 20F). In agreement with our hypothesis, both 
VU0405645 (Fig. 20F) and VU0405652 (Fig. 20G, H) blocked CCh-induced LTD (Fig. 
20H). Collectively, these findings demonstrate a role of PLD in this cortical M1-LTD and 
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show that biased M1 receptor PAMs not only fail to potentiate a submaximal concentration 
of CCh-LTD, but can also actively block a maximal concentration of CCh-LTD. 
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Figure 21: Biased M1 PAMs fail to potentiate a submaximal mLTD in the mPFC and 
actively block CCh-dependent LTD.  
(A) Left: Time course graph for fEPSP slope normalized to the average baseline. Right: 
Comparison of fEPSP slope during baseline and 46-50 min after carbachol (10 μM, CCh) 
washout (shaded area). 10 min bath application of CCh (10 μM) induces a minimal long-
term depression (LTD) of fEPSP slope (88.9 ± 6.05, n/N= 15/13 slices/mice; paired t-test; 
p > 0.05). (B) 10 min pretreatment of the nonbiased M1 PAM VU0453595 (10 μM), 
followed by a 10 min co-application of VU0453595 + CCh (10 μM) (81.5 ± 4.70%, n/N= 
14/11; paired t-test P = 0.01). (C) 10 min pretreatment of the biased M1 PAM VU0405652 
(10 μM), followed by a 10 min co-application of VU0405652 + 10 μM CCh (93.5 ± 3.28%, 
n/N= 9/8; paired t-test; P > 0.05). (D) 10 min pretreatment of the biased M1 PAM 
VU0405645 (10 μM), followed by a 10 min co-application of VU0405645 + CCh (10 μM) 
(91.9 ± 4.67%, n/N= 7/7; paired t-test; P > 0.05). Insets contain representative fEPSP 
traces for each condition for baseline (red trace) and 50 min after CCh washout (black 
trace), scale bars denote 0.5 mV and 5 ms and data are expressed as mean ± SEM. **P 
≤ 0.01. (E) Summary of the last 5 min of the recordings from the time course experiments 
(& =  P < 0.05, paired t-test). (F) Left: Time course graph for fEPSP slope normalized to 
the average baseline. CCh (50 μM, black) (70.0 ± 7.78%, n/N= 9/7) alone compared to 
10 min pretreatment with VU0405645 (10 µM) and 10 min co-application of CCh (50 µM, 
white) (101 ± 8.59%, n/N= 11/8). Right: representative fEPSP traces for each condition 
for baseline (red trace) and 50 min after CCh washout (black trace), scale bars denote 
0.5 mV and 5 ms. (G) Time course graph of normalized fEPSP slope of 10 min 
pretreatment VU0405652 (75 µM) and 10 min co-application of CCh (50 μM, red) (102 ± 
9.46%, n/N= 7/3) compared to CCh alone (shaded time course correspond to CCh (50 
μM) from the previous panel; the solid, white line represents the mean fEPSP slope and 
the gray-shaded region around the line shows ± SEM). (H) Quantification of the average 
fEPSP slope 46–50 min following CCh washout (shaded area) (one-way ANOVA F3,25 = 
4.554; p = 0.0216, with a post-hoc Dunnett’s test using CCh alone as the control group, * 
P < 0.05).  
PLD is not necessary for the M1 receptor–dependent increase of layer V sEPSC 
in the mPFC 
 In light of these findings, we next set out to determine whether PLD is important in 
other M1-dependent functions in the CNS. Previously, we reported that M1 receptor 
activation increases the frequency of spontaneous excitatory postsynaptic currents 
(sEPSC) in mPFC layer V pyramidal neurons (46, 52, 57).  In agreement with these 
previous findings, bath application of a maximal concentration of CCh induced a robust 
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increase in sEPSC frequency in layer V pyramidal neurons (Fig. 21A). In contrast to M1-
dependent LTD, the effect of CCh on sEPSCs was unchanged by pretreatment and co-
application of the dual PLD inhibitor ML299 (Fig. 21B). Quantification of the peak CCh 
effect on sEPSC frequency indicated no statistically significant difference between CCh 
alone and CCh in the presence of ML299 (Fig. 21C). These data suggest that PLD is not 
necessary for this M1-dependent increase of sEPSC frequency in mPFC layer V 
pyramidal neurons. 
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Figure 22: PLD is not required for the M1-dependent increase in sEPSC frequency 
in mPFC layer V pyramidal neurons, and both biased and nonbiased M1 PAMs 
potentiate this response. 
 (A) Sample traces (left) and the cumulative probability of interevent interval (IEI) (right) 
of sEPSCs in baseline) during application of CCh (100 µM) as indicted for a typical cell. 
(B) Sample traces (left) and the IEI cumulative probability (right) of sEPSCs in baseline 
with PLD1,2 inhibitor ML299 (2 µM) and during application of a combination of ML299 and 
CCh (100 µM) for a typical cell. (C) Quantification of the average increase in sEPSC 
frequency between CCh alone (357.0 ± 81.6%, n/N = 7/3 cells/animals) and CCh in the 
presence of ML299 (427.0 ± 76.5%, n/N = 8/3) (Student’s t-test; P > 0.05). (D) Sample 
traces (left) and IEI cumulative probability (right) of sEPSCs in baseline and during 
application of CCh (10 µM) from a typical cell. (E to G) Sample traces (left) and IEI 
cumulative probability (right) of sEPSCs in baseline, during application of a PAM) and the 
PAM with CCh as indicated for typical cells are shown. (H) Quantification of the peak 
effect on sEPSC frequency for CCh (10 µM) alone (147 ± 15.4%, n/N = 7/3), CCh with 
VU0453595 (10 μM) (416 ± 38.2%, n/N = 8/4), CCh with VU0405652 (10 μM) (316 ± 
43.3%, n/N = 10/5), and CCh with VU0405645 (10 μM) (332.4 ± 63.7%, n/N = 11/4). one-
way ANOVA F3,35 = 5.77; P = 0.0026, with a post-hoc Dunnett’s test using CCh alone as 
the control group, *P < 0.05, **P < 0.01. Data are expressed as mean ± SEM. (I) 
Schematic of whole-cell recordings from mPFC layer V pyramidal neurons (regular 
spiking cells) clamped at −70 mV. 
Next, we sought to compare the two biased M1 receptor PAMs, VU0405652 and 
VU0405645, to our prototypical M1 receptor PAM, VU0453595, in their ability to potentiate 
a submaximal concentration of CCh-induced increases in mPFC layer V pyramidal 
neuron sEPSC frequency. As expected, bath application of a submaximal concentration 
of CCh did not induce a significant change in sEPSC frequency (Fig. 21D). Similar to the 
M1 receptor PAM BQCA (46), the non-biased M1 receptor PAM VU0453595 induced a 
robust potentiation of the effect of a submaximal concentration of CCh on sEPSC 
frequency (Fig. 21E) and this effect was attenuated by pharmacological inhibition of PLC 
with the PLC inhibitor U73122 (Fig. 22A-D). Consistent with the studies with PLD 
inhibitors, both VU0405652 (Fig. 21F) and VU0405645 (Fig. 21G) potentiated agonist-
induced increases in sEPSC frequency. Quantification of the peak effect on sEPSC 
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frequency indicated a statistically significant difference between CCh alone and all three 
M1 receptor PAMs (Fig. 21H). Therefore, both biased and non-biased M1 receptor PAMs 
function similarly in their ability to potentiate a submaximal concentration of agonist-
induced increases in mPFC layer V pyramidal neuron sEPSC frequency (Fig. 21I). 
 
Figure 23: M1 receptor PAM potentiation of CCh-induced increases in mPFC layer 
V pyramidal neuron sEPSC frequency is phospholipase C dependent.   
(A) Sample traces during bath application of CCh (10 µM) in the presence of DMSO ACSF 
for a typical cell. (B) Sample trace during bath application of DMSO ACSF, VU0453595 
(10 µM) + DMSO ACSF then VU0453595 (10 µM) + CCh (10 µM) + DMSO ACSF for a 
typical cell. (C) Sample trace during bath application of U73122 (10 µM), U73122 (10 µM) 
+ VU0453595 (10 µM) then U73122 (10 µM) + VU0453595 (10 µM) + CCh (10 µM). (D) 
Quantification of the peak effect on sEPSC frequency for CCh (10 µM) in the presence of 
DMSO (177.5 ± 19.0%, n/N = 6/3), CCh + VU0453595 (10 μM) + DMSO (542.0 ± 112.3%, 
n/N = 7/3), CCh + VU0453595 (10 μM) + U73122 (10 µM) (265.9 ± 47.2%, n/N = 7/3. one-
way ANOVA F3,19 = 6.467; P = 0.0082, with a post-hoc Dunnett’s test using VU0453595 
(10 µM) + CCh (10 µM) in the presence of DMSO ACSF as the control group, *P < 0.05, 
**P < 0.01. Data are expressed as mean ± SEM.   
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PLD is not necessary for the effects of the M1 receptor on the excitability of 
striatal SPNs 
 The M1 receptor is also highly expressed in the striatum (34), and we have shown 
that M1 receptor activation in spiny projection neurons (SPN) in the dorsal lateral striatum 
leads to a robust increase in SPN excitability that can be blocked by a selective M1 
receptor antagonist (70, 108). Therefore, we set out to determine whether PLD is required 
for this M1-dependent response. As expected, bath application of CCh induced a robust 
increase in dorsal lateral striatum SPN excitability (Fig. 23A). In the presence of the dual 
PLD inhibitor ML299, CCh still induced a marked increase in SPN excitability compared 
to baseline (Fig. 23B). Quantification of the CCh-induced increase in SPN excitability 
showed no significant difference between the change in number of spikes per pulse 
between control (DMSO) and ML299 groups (Fig. 23C). Therefore, similar to the sEPSC 
findings, PLD is not necessary for M1-dependent increases in dorsal lateral SPN 
excitability. 
 The finding that PLD is not involved in M1 receptor regulation of SPN excitability 
suggests that biased M1 receptor PAMs that selectively potentiate coupling to PLC and 
do not potentiate PLD activity would function similarly to non-biased M1 receptor PAMs in 
their ability to potentiate responses to a low concentration of CCh on SPN excitability. In 
agreement with our previous findings (108), a submaximal concentration of CCh induced 
a minimal increase in SPN excitability (Fig. 23D) that was robustly potentiated by the 
prototypical M1 receptor PAM VU0453595 (Fig. 23E). As expected, both VU0405652 (Fig. 
23F) and VU0405645 (Fig. 23G) potentiated a submaximal concentration of CCh-induced 
increase of SPN excitability. The maximal increase in the number of spike discharges 
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during agonist application was significantly higher in the presence of each of the three M1 
receptor PAMs compared to the DMSO control condition (Fig. 23H-I). Interestingly, in 
these studies the concentration of VU0453595 used induced a more robust effect than 
did these concentrations of VU040652 or VU0405645. However, based on the current 
results, it is unclear whether the concentrations used provide a maximal effect on SPN 
excitability. Thus, it is not clear whether this apparent difference represents differences in 
relative efficacies of the different PAMs or differences in slice penetration and final 
concentrations at the M1 receptor. However, these results demonstrated that biased and 
non-biased M1 receptor PAMs function similarly in their ability to potentiate M1-dependent 
regulation of SPN excitability and other CNS responses that are PLD-independent. 
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Figure 24: PLD is not necessary for M1-dependent effects on the excitability of 
striatal SPNs, and both biased and nonbiased M1 PAMs potentiate this response.  
(A) Sample traces of membrane potential responses to a depolarization current step from 
an SPN during baseline, in the presence of DMSO and CCh (10 µM).  (B) Effect of 
pretreatment of ML299 (2 µM) then co-application of carbachol on SPN excitability (10 
µM). (C) Bar graph summarizing the changes in the number of spikes per pulse after CCh 
(10 µM) application in presence of ML299 (12.0 ± 3.38, n/N = 6/5 cells/animal) or DMSO 
(16.9 ± 4.67, n/N = 5/5) shows no significant difference between groups (Student’s t-test; 
P > 0.05). (D to G) Sample traces of membrane potential responses to a depolarization 
current step from an SPN during baseline, in the presence of M1 PAM (3 µM) or DMSO, 
then M1 PAM/DMSO + CCh (0.5 µM). (H) Bar graph summarizing the change in the 
number of spikes per pulse after CCh (0.5 µM) application in presence of DMSO (1.83 ± 
0.49, n/N = 9/7), VU0453595 (14.2 ± 3.05, n/N = 6/6), VU0405652 (9.02 ± 2.31, n/N = 
7/6) and VU0405645 (9.00 ± 2.37, n/N = 6/5) (one-way ANOVA F3,24 = 6; P = 0.0017, with 
a post-hoc Dunnett’s test using CCh + DMSO as the control group,  *P < 0.05, ***P < 
0.001). Data are expressed as mean ± SEM. (I) Schematic of whole-cell recordings from 
SPN neurons under current clamp conditions performed in the DLS.  
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Discussion  
 A large body of clinical and preclinical research suggests that enhancing mAChR 
signaling can be efficacious in the treatment of the cognitive symptoms associated with 
Alzheimer’s disease and schizophrenia (17, 19, 109, 110). Although multiple mAChR 
subtypes are involved in the regulation of cognitive function, most preclinical studies point 
to a dominant role of the M1 receptor and suggest that its selective modulation may 
provide a therapeutic potential for the treatment of these devastating cognitive symptoms 
(36, 41, 46, 48, 49, 52, 53, 55, 57, 76, 80, 82, 111). However, M1 receptors regulate CNS 
function by actions on multiple signaling pathways, and M1 receptor PAMs can display a 
diverse range of pharmacological properties, including signal bias. At present, little is 
known about the specific signaling pathways involved in the different physiological effects 
of M1 receptor activation and how signal bias can affect the PAM-mediated modulation of 
M1 receptor actions in identified brain circuits.  
 The present studies improve our understanding of at least one mechanism by 
which M1 receptor activation leads to plasticity changes within a key cortical structure in 
the CNS. Specifically, we found that a previously described M1-dependent LTD in the 
cortex was dependent on the activation of PLD. Furthermore, we identified M1 receptor 
PAMs that selectively enhanced M1 receptor coupling to PLC but not PLD, and found that 
these biased M1 receptor PAMs failed to potentiate this form of M1-dependent LTD. 
Finally, these biased M1 receptor PAMs actively blocked the ability of mAChR agonists to 
induce this PLD-dependent LTD, consistent with the hypothesis that these PAMs stabilize 
a conformation of the M1 receptor that favors activation of PLC over PLD and thereby bias 
M1 receptor signaling in favor of PLC-mediated responses. Furthermore, not all M1-
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dependent responses were PLD-dependent, and biased M1 receptor PAMs functioned 
similarly to nonbiased M1 PAMs in M1 signaling that was PLD-independent. 
 Although the ability of the M1 receptor and other GPCRs to activate PLD is well 
established (112), little is known about the physiological roles of PLD in regulating CNS 
function. This has largely been due to the lack of selective inhibitors and other tools that 
enable systematic studies of PLD-mediated responses. However, the discovery of the 
highly selective PLD inhibitors used here (99–101), together with the generation of PLD 
KO mice and the biased M1 receptor PAMs reported in the present studies, provided an 
unprecedented opportunity to determine the roles of PLD in mediating specific responses 
to M1 receptor activation. With the availability of these new tools, these studies provide 
an example of a specific physiological role of PLD in mediating a response to GPCR 
activation in the CNS and reveal a previously uncharacterized role for PLD in the induction 
of major form of synaptic plasticity in an identified brain circuit. Furthermore, these PLD 
inhibitors include selective inhibitors of PLD1 and PLD2, the major isoforms of PLD 
expressed in the CNS. Experiments with these isoform-selective inhibitors, together with 
PLD1 KO mice, revealed a critical role for PLD1 as the PLD isoform involved in mediating 
this response to M1 receptor activation. 
 M1-dependent LTD in the mPFC has been extensively studied and has been 
postulated to play a critical role in regulating specific inputs to the mPFC from the 
hippocampus and other extrinsic afferents (58, 113). Cholinergic regulation of these 
inputs is thought to be important for the regulation of multiple aspects of mPFC function 
and previous studies suggest that M1 receptor expression and signaling in the mPFC can 
be impaired in some pathological states that could be relevant for schizophrenia and 
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Alzheimer’s disease (52, 53, 114–121). However, very few studies have focused on 
understanding the cellular mechanisms underlying M1-dependent LTD in the PFC. 
Although the current studies identify PLD1 as being critically important in M1-dependent 
cortical synaptic plasticity, the detailed molecular mechanism by which the M1 receptor 
signals through PLD to induce synaptic plasticity changes in the cortex remains unknown. 
Rigorous molecular and biochemical studies to elucidate this signaling pathway are 
necessary to fully understand the signaling cascade responsible for M1-dependent LTD. 
 The finding that PLD1 is important for this form of synaptic plasticity, coupled with 
the finding that biased and nonbiased M1 receptor PAMs have functionally distinct effects 
on this response, raises the possibility that different PAMs could have unique profiles in 
regulating cognitive function or other in vivo responses. It is possible that biased versus 
nonbiased M1 receptor PAMs could induce markedly different effects on specific 
behavioral responses, as is the case for biased and nonbiased PAMs of the mGlu5 
subtype of metabotropic glutamate (mGlu) receptor (122, 123). Unfortunately, the 
currently available biased M1 receptor PAMs used in the present studies do not have 
appropriate properties to enable their use in behavioral studies in vivo (Table 3). However, 
in future studies, it may be possible to optimize biased M1 receptor PAMs that can be 
used to systematically evaluate the roles of PLD in specific behavioral responses that are 
dependent on M1 receptor activation. Extensive drug discovery efforts are needed to 
develop biased M1 receptor PAMs that have favorable physical and pharmacokinetic 
properties suitable for systemic administration with high CNS penetrance to test whether 
systemically administered biased M1 PAMs display functional differences in their ability to 
reverse the cognitive deficits in preclinical animals relevant for AD and schizophrenia. 
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Compound 
Molecular 
Weight 
Route 
[Dose] 
TIME 
(min) 
Plasma 
Concentration  
(ng/mL) 
Plasma 
Concentration 
(nM) 
Brain 
Concentration 
(ng/mL) 
Brain 
Concentration 
(nM) 
VU0405652 505.35 i.p. 
[30mg/kg] 
15  3380 6688 68.7 135.95 
30  1641 3247 157 310.68 
  
VU0405645 511.51 i.p. 
[30mg/kg] 
15  0.00 0.00 6.51 12.73 
30  8.48 16.58 13 25.41 
 
Table 3: Summary of the in vivo pharmacological characterization data for 
VU0405652 and VU0405645. 
Data represent mean values (n=3). 
 Lastly, future studies are necessary to develop an understanding of the precise 
molecular mechanisms involved in conferring bias for some M1 receptor PAMs. Whereas 
there are multiple examples of allosteric modulators of GPCRs that induce biased 
signaling, little is known about the structural basis of biased versus nonbiased signaling. 
Previous studies revealed multiple allosteric binding sites for some GPCRs, which could 
contribute to different responses to distinct classes of allosteric modulators (124–126). 
However, other studies suggest that differences in M1 receptor PAM functionality may not 
be due to binding to different allosteric binding pockets, but that binding of PAMs to a 
single allosteric site may stabilize different receptor conformational states (23, 127). 
Understanding how allosteric modulators of GPCRs induce their effects will help facilitate 
the rational design of the next generation of PAMs and negative allosteric modulators. 
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CHAPTER 4 
SUMMARY & DISCUSSION 
Summary 
In conclusion, the high-profile failure of several experimental therapeutic 
approaches targeting the reduction of Aβ in patients with AD warrants identification and 
development of novel therapeutic targets for the treatment of the cognitive disruptions in 
AD. Furthermore, current antipsychotics do not improve and may even worsen the 
cognitive deficits associated with schizophrenia (128). The ability of M1 PAMs to improve 
cognition in multiple animal models (36, 48, 52, 53, 57, 82) suggest a strong potential for 
success in the clinic and may help mitigate the critical issue common to animal models in 
that they often fail to recapitulate the full range of disease symptoms and etiology. 
However, with the recent phase II failure of MK-7622 to significantly improve cognitive 
endpoints in AD patients (74), there is a critical need to fully characterize M1 PAMs with 
respect to agonist activity, signal bias, and other pharmacological properties in order to 
de-risk clinical candidates and move the M1 PAM with the highest chance of success 
forward into the clinic.  
Discussion 
Overactivation of the M1 mAChR may be detrimental to M1 PAM efficacy 
The findings outlined in Chapter 2 suggest that the in vivo cognition-enhancing 
efficacy of M1 PAMs can be observed with PAMs lacking agonist activity and that intrinsic 
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agonist activity of M1 PAMs may contribute to adverse effects and result in reduced 
efficacy in improving cognitive function. Furthermore, as receptor expression levels may 
vary between cell lines and between research groups, it is critical to evaluate M1 
preclinical candidates in systems with varying degrees of receptor reserve (i.e. both in 
vitro and in native tissue) to fully characterize potential ago-PAM activity. 
 While in vitro assays are ideal to screen compounds and achieve a first pass look 
at a ligand’s pharmacological properties, cell-based assays often fail to recapitulate the 
exact pathways found in native tissue. Additionally, discovery and characterization of 
functional M1 receptors expressed intracellularly (129), as well as allosteric ligands that 
display “signal  bias” (90), further highlights the need to fully assess activities of allosteric 
modulators in native preparations. Full understanding of the pharmacological properties 
responsible for in vivo efficacy of other GPCR allosteric ligands, such as mGlu5 PAMs 
that display stimulus bias, have provided proof-of-concept that adverse effect liability can 
be avoided and in vivo efficacy remain intact (122).  
M1 PAMs that display bias can have differential effects in the CNS 
Characterization of a broad range of structurally diverse M1 PAMs revealed an 
interesting signal bias in that some M1 PAMs can potentiate receptor signaling through 
the canonical phospholipase C (PLC) pathway, but do not potentiate M1 receptor–
mediated activation of phospholipase D (PLD) (90). Little was known about the role of 
PLD in M1 signaling in the CNS and whether PLD is necessary for any M1-dependent 
signaling. First, we demonstrated that activation of the M1 mAChR primarily couple to 
PLD1 not PLD2 in M1 mAChR expressing CHO cells. Interestingly, these findings were 
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recently recapitulated in immortalized HeLa cells (130). These two findings suggest that 
while PLD1 and PLD2 can catalyze the same enzymatic reaction, they have non-
redundant functions with respect to GPCR signaling. 
 Using brain slice electrophysiology, in Chapter 3 we demonstrated that not all M1-
dependent responses in the CNS were PLD-dependent, and biased M1 PAMs functioned 
similarly to nonbiased M1 PAMs in M1 signaling that was PLD-independent. However, M1 
PAMs that do not couple to PLD function in a dramatically different way than nonbiased 
M1 PAMs in their ability to potentiate a PLD-dependent M1-mediated plasticity in the PFC. 
These findings demonstrate that PLD plays a critical role in the ability of M1 PAMs to 
modulate certain CNS functions and that biased M1 PAMs function differently in synaptic 
plasticity in the cortex implicated in cognition.  
   
Future Directions 
Characterization of M1 signaling pathway to phospholipase D 
 Although the current studies identify PLD1 as being critically important in M1-
dependent cortical synaptic plasticity, the detailed molecular mechanism by which the M1 
receptor signals through PLD to induce synaptic plasticity changes in the cortex remains 
unknown. Rigorous molecular and biochemical studies to elucidate this signaling pathway 
are necessary to fully understand the signaling cascade responsible for M1-dependent 
LTD.  
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 In order to elucidate the molecular mechanisms that govern M1 mAChR signaling 
to PLD, it would be most prudent to start in a cell culture system (e.g. M1 mAChR 
expressing CHO cells) in order to quickly screen through different downstream signaling 
effectors. Utilizing RNAi based technologies such as small interfering RNA (siRNA) (131–
133), in combination with the PLD assay, it would be feasible to quickly screen different 
downstream effectors (i.e. AKT, PLC, mTOR, various g-proteins etc.). Preliminary data in 
Fig. 24A suggest that neither K-Ras nor H-Ras play a role in M1 mAChR activation of 
PLD. Results in Fig. 24B suggest a potential role of PI3K, AKT, Src, GSK3, PKC and 
possibly mTOR in M1 activation of PLD in M1 mAChR expressing CHO cells. While 
promising, these results are from just one assay and need to be replicated and the various 
protein knockdown confirmed by western blot analysis.    
 
Figure 25. Preliminary data examining the signaling pathway involved in M1 
mAChR activation of PLD.  
(A) Use of CHO cells expressing normal H-Ras and K-Ras proteins or the dominant 
negative mutations forms of this protein. (B) PLD activation by CCh appears to be 
decreased by pharmacological inhibition of PI3K, AKT, Src, GSK3, PKC and potentially 
mTOR but not MEK. N=1 assay (3 lanes averaged together) per group. Data courtesy of 
Hyekyung Plumley.  
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 It should be noted that siRNA technology suffers from the caveat of off target 
effects as well as the fact that siRNA knockdown of the transcript of interest in typically 
not 100% and small amounts of transcript may be sufficient to provide a full response, 
thereby confounding the interpretation of the results. Therefore, newer technologies using 
the Crispr-Cas system can be used to permanently delete or alter the gene of interest 
(134) or to selectively repress the expression of targeted genes through the use of 
CRISPR interference (CRISPRi) with no detectable off-target effects (135). Together, 
through these cell based experiments, we could quickly screen putative signaling 
molecules upstream of PLD and then determine whether the protein of interest is also 
critical for M1 mAChR signaling in native tissue assays such as CCh-LTD in the mPFC. 
Role of PLD downstream of other canonical Gαq GPCR signaling 
 The M1 mAChR is one of many different receptors that can couple to PLD, and 
PLD is known to be activated by both multiple classes of GPCRs as well as receptor 
tyrosine kinases (136). Previously, it was demonstrated that the activation of mGlu 
receptors can lead to activation of PLD in cell lines as well as in hippocampal slice 
preparations (137–139). Furthermore, mGlu receptor activation of PLD was 
demonstrated to be independent of both PLC and PKC. However, the dearth of 
pharmacological and genetic tools available at the time prevented further investigation 
into the role of PLD in mGlu receptor signaling. With the recent significant advances in 
mGlu receptor subtype selective inhibitors, highly selective mGlu receptor PAMs, and 
PLD isoform selective inhibitors, we are now poised to revisit the role of PLD in mGlu 
receptor signaling.  
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 Based on the previous literature, we do not know which specific mGlu receptors 
subtypes may or may not couple to PLD, we do know that activation of both group I and 
group II mGlu receptors by 1S,3R-amino-1,3-cyclopentanedicarboxylic acid (ACPD) can 
lead to increases in PLD. Therefore, we set out with the initial goal to determine whether 
group I mGlu receptors (mGlu1 and mGlu5) couple to PLD. Thus, we set out to test 
whether PLD was involved in a group I mGlu receptor-LTD at SC-CA1 in the hippocampus 
induced by (S)-3,5-Dihydroxyphenylglycine (DHPG), a very well characterized form of 
synaptic plasticity involving group I mGlu receptors. Importantly, previous studies have 
demonstrated that DHPG-LTD at SC-CA1 in the hippocampus is not dependent on PLC 
or PKC (140, 141), and therefore is a good candidate for being dependent on non-
canonical signaling proteins such as PLD. 
 Preliminary results from these studies demonstrate that, similar to the CCh-LTD in 
the mPFC, DHPG-LTD in the hippocampus is dependent on PLD1 not PLD2 (Fig. 25A-F). 
Confirming these results, PLD1 KO mice have a significant deficit in DHPG-LTD compared 
to littermate controls. Since DHPG can activate both mGlu1 and mGlu5, we then probed 
whether an mGlu5 specific LTD in the hippocampus was also dependent on PLD. We 
previously demonstrated that bath application of the mGlu5 ago-PAM VU0424465 can 
produce a robust mGlu5 LTD at SC-CA1 in brain slices obtained from rodents (67). In 
agreement with the previously published data, we demonstrated that VU0424465 
produced a robust LTD (Fig. 25J) and that this mGlu5-LTD was absent in the presence of 
the PLD1 inhibitor (Fig. 25K-L). Therefore, these preliminary findings suggest that mGlu5 
may couple to PLD and that PLD1 may be critical for some forms of mGlu receptor 
synaptic plasticity in the hippocampus.  
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 While these preliminary findings are exciting, detailed future studies are necessary 
to fully probe the role of PLD in mGlu receptor signaling. In order to determine which 
specific mGlu receptor subtypes couple to PLD, PLD activity can be directly quantified 
using mGlu receptor-expressing HEK cells for the PLD assay. Furthermore, this cell-
based assay can be used to probe the signaling cascade involved in mGlu receptor 
coupling to PLD.  
 While DHPG-LTD is a well characterized form of mGlu receptor synaptic plasticity 
in the hippocampus, it would be interesting to probe the role of PLD in other forms of 
mGlu-dependent synaptic plasticity including: electrically-induced LTD (low frequency 
stimulation (LFS) as well as paired pulse-LFS (PP-LFS), high frequency stimulation LTP 
and theta burst stimulation LTP. Understanding whether PLD is involved in any of these 
other forms of synaptic plasticity would greatly advance the field of  hippocampal synaptic 
plasticity as well as help focus on PLD-impacted signaling pathways. 
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Figure 26: DHPG-LTD at SC-CA1 in the hippocampus is dependent on PLD, 
specifically PLD1  
(A) Schematic of SC-CA1 hippocampal brain slice (B) Bath application of 50µ M DHPG 
results in a long-term depression (LTD) of fEPSPs. (C) pretreatment with the PLD1,2 
inhibitor ML299 blocks this LTD. (D) Inhibition of PLD1 but not (E) PLD2 blocks DHPG-
LTD. (F) Oneway ANOVA with Dunnett’s post-hoc test demonstrates a significant 
difference between PLD1,2 inhibition, PLD1 inhibition but not  PLD2 inhibition compared to 
DHPG alone. (G-H) DHPG-LTD is attenuated in PLD1 KO mice but not littermate controls. 
(I) Student’s t-test demonstrates significant difference between genotype. (J) mGlu5 ago-
PAM VU0424465 induces a mGlu5-dependent LTD that is lost in the presence of the (K) 
PLD1 inhibitor. (L) Student’s t-test demonstrates significant difference between two 
groups. 
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Development of the next generation of biased M1 PAMs  
 Extensive medicinal chemistry efforts are needed to develop biased M1 mAChR 
PAMs that have favorable physical and pharmacokinetic properties suitable for systemic 
administration with high CNS penetrance to test whether systemically administered 
biased M1 PAMs display functional differences in their ability to reverse the cognitive 
deficits in preclinical animals relevant for AD and schizophrenia. Results from these 
studies could directly impact drug discovery decisions for backup compounds and/or 
future clinical candidates.  
Furthermore, it would be especially useful to develop M1 PAMs that potentiate 
coupling to PLD but not PLC. An M1 PAM with this pharmacological property could be 
very useful to test whether M1 PAM coupling to PLC is necessary or sufficient for M1 PAM 
efficacy and/or adverse effects in vivo. However, identification of a biased M1 PAM that 
couples to PLD but not PLC is currently challenging due to the low-throughput manner of 
the PLD activity assay. A solution to this technical problem can be solved by development 
of a higher-throughput PLD activity assay that would likely use fluorescence as a read out 
instead of quantifying radioactivity using film. One possibility is to develop a fluorescent 
reporter that changes light emission with respect to generation of the stable PLD product 
phosphatidylbutanol. In theory, this could be similar to the calcium mobilization assay dye 
Fluo-4 AM that exhibits an increase in fluorescence upon binding of Ca2+. A similar 
approach would be to use the recently developed PLD “click-chemistry” technology that 
correlates PLD activity with a change in fluorescence (130). 
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 Fluorescence-activity assays are extremely amendable to high-throughput 
screening and therefore, a large library of compounds can be screened. One could also 
envision a “smart” library of small molecules that are structurally similar to established M1 
PAMs that have weak activity, no activity, or inverse agonism in the M1 CHO cell Ca2+ 
mobilization assay. In theory, this intelligently designed “smart” library could have a higher 
chance of success in identifying an M1 PAM that does not potentiate PLC but does 
potentiate PLD. identified leads would then need to be counter-screened in receptor 
subtype selectivity, in vivo pharmacokinetic assays, and native tissue assays.  
Lastly, PLC and PLD are just two out of many different signaling pathways 
downstream of the M1 mAChR and future studies are necessary to identify M1 PAMs with 
favorable in vivo properties that may display signal bias for other signaling pathways 
including ERK or β-arrestin, in order to fully dissect the downstream signaling pathways 
important for M1 PAM efficacy and adverse effect liability. To date, no biased M1 PAMs 
with respect to ERK phosphorylation or β-arrestin recruitment have been disclosed; 
however, only a small number of M1 PAMs have been tested (41, 44, 45).  
Characterization of the molecular mechanisms involved in conferring bias 
 Future studies are necessary to develop an understanding of the precise molecular 
mechanisms involved in conferring bias for M1 receptor PAMs. Whereas there are multiple 
examples of allosteric modulators of GPCRs that induce biased signaling, little is known 
about the structural basis of biased versus nonbiased signaling. Previous studies have 
revealed multiple allosteric binding sites for other GPCRs such as mGlu receptors, and 
these distinct binding sites could contribute to the different responses to distinct allosteric 
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modulators (124–126). However, investigation into the binding sites of M1 PAMs has 
revelaed that several structurally distinct M1 PAMs (e.g. PF-06767832, MIPS1780, 
VU6004256) bind to the same binding pocket as the first described M1 PAM, BQCA (127, 
142).  
 Therefore, differences in M1 mAChR PAM functionality may not be due to the 
allosteric ligand binding to a different allosteric binding pocket, but instead be due to the 
binding of PAMs to the same allosteric site but stabilizing different receptor 
conformational states (23, 127). This is further supported by the hypothesis that M1 PAM 
selectivity for the M1 mAChR, compared to the other mAChR subtypes, is not driven by 
binding to a unique allosteric site on the M1 mAChR; rather, subtype-selectivity is driven 
by cooperativity (142, 143). Thus, understanding exactly how allosteric modulators of 
GPCRs induce their effects may help facilitate the rational design of the next generation 
of PAMs and negative allosteric modulators.  
M1 PAMs with low α-values may also minimize adverse effects 
According to the operational allosteric ternary complex model (22, 144), allosteric 
modulators can exert their effects by modulating binding affinity of the orthosteric agonist 
(e.g. binding of ACh to the M1 mAChR) or by modulating receptor efficacy (e.g. ACh 
response), termed α and β respectively (Fig. 26A). When α > 1, the allosteric modulator 
increases the affinity of the orthosteric agonist whereas when α < 1 demonstrates a 
decrease in receptor-agonist affinity. Conversely, when β > 1, the allosteric modulator will 
potentiate cellular activation whereas when β < 1, the modulator will prevent cellular 
activation (Fig. 26B). Importantly, α and β values are independent of each other and in 
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theory can occur in every combination (144). Several recent papers from Takeda 
Pharmaceutical Company Ltd suggest that M1 PAMs that possess low α-values, such as 
TAK-071, have a wider therapeutic index in rodent models relevant for schizophrenia 
compared to M1 PAMs with high α-values (81, 145, 146). However, TAK-071 was not 
completely devoid of adverse effects and demonstrated a concentration-dependent 
increase in spontaneous ileum motility (145). Nonetheless, TAK-071 provides a much 
greater margin between doses leading to cognition-enhancing effects and adverse effects 
(e.g. diarrhea) compared to T-662, an M1 PAM with a high α-value (81, 111, 145). 
Furthermore, it is not known whether M1 PAMs with higher α and β-values may be more 
beneficial in later stages of AD in which there is greater loss of endogenous ACh (15, 
147). Overall, while these results are promising, more extensive studies are necessary to 
understand the exact relationship between α-value, agonist activity, and signal bias to 
fully characterize the pharmacological profiles of M1 PAMs. Lastly, it is prudent to carefully 
consider the appropriate α and β-values for the M1 PAM clinical candidate depending on 
the stage of AD (e.g. early or late) chosen for clinical intervention.  
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Figure 27: Allosteric modulator modes of action.  
(A) Allosteric modulators (yellow square) bind to a topographically and structurally distinct 
site on the muscarinic receptor to modulate orthosteric agonist (acetylcholine, pink) 
affinity (red) and/or efficacy (blue). Binding of allosteric agonists or ago-PAMs can also 
directly induce receptor signaling in the absence of the orthosteric agonist (green). (B) 
Left: Allosteric modulators that robustly modulate agonist affinity (high α-value, red) will 
result in a large leftward shift in the orthosteric agonist concentration response curve. In 
contrast, allosteric modulators that weakly enhance agonist affinity (low α-value, grey) 
result in a modest leftward shift in the orthosteric agonist concentration response curve. 
Right: Allosteric modulators that strongly modulate agonist efficacy (high β-value, red) 
may result in a large increase in the orthosteric agonist maximal response. In contrast, 
allosteric modulators that weakly enhance agonist efficacy (low β-value, grey) result in a 
modest increase in the orthosteric agonist response. Sigmoidal curves were generated 
using Graphpad Prisim8 (www.graphpad.com).  
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Potential utility of M1 allosteric modulators for the treatment of other CNS 
disorders 
In addition to potential efficacy in reversing cognitive deficits in AD and 
schizophrenia patients, recent studies suggests that M1 PAMs also improve social 
interactions in rodent models (52). Previously, xanomeline demonstrated efficacy in 
reducing negative symptoms in schizophrenia patients (18, 19), thus, it will be important 
to fully evaluate the potential efficacy of M1 PAMs in animal models that are relevant for 
negative symptoms. To this same end, the wide variety of M1 and M4 selective tool 
compounds developed over the past decade have identified other psychiatric and 
neurological disorders in which subtype-selective muscarinic modulation may be 
effective. Consistent with procognitive efficacy, the M1 PAM BQCA improved learning and 
memory deficits in a rodent model of traumatic brain injury (148). An M1 PAM was also 
able to enhance the consolidation and recall of fear extinction in a rodent model of 
posttraumatic stress disorder (PTSD) (58) suggesting that M1 PAMs could improve the 
efficacy of exposure therapy in the clinic for the treatment of PTSD and other anxiety 
disorders 
In addition to AD and schizophrenia, the wide variety of M1 selective tool 
compounds developed over the past decade have identified other psychiatric and 
neurological disorders in which subtype-selective muscarinic modulation may be 
effective. Consistent with procognitive efficacy, the M1 PAM BQCA improved learning and 
memory deficits in a rodent model of traumatic brain injury (148). An M1 PAM was also 
able to enhance the consolidation and recall of fear extinction in a rodent model of 
posttraumatic stress disorder (PTSD) (58) suggesting that M1 PAMs could improve the 
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efficacy of exposure therapy in the clinic for the treatment of PTSD and other anxiety 
disorders. Additionally, M1 activation in combination with an M4 PAM accelerated the 
extinction of cocaine seeking (149) implying that potentiating M1 activation may broadly 
facilitate and/or enhance extinction learning across multiple behavioral paradigms. 
Therefore, future studies are needed to determine whether M1 PAMs could be beneficial 
in a broader range of CNS disorders.  
Conclusions 
 A wealth of preclinical literature over the last decade suggest that allosteric 
modulators of several mAChRs hold great promise for the treatment of multiple 
devastating CNS disorders, including AD, schizophrenia and other brain disorders, which 
have limited to no effective treatments. Recent advances in medicinal chemistry efforts 
to develop highly selective mAChR ligands have provided fundamental new insights into 
muscarinic receptor biology as well as provided key information for drug discovery efforts. 
As a consequence of these efforts, several allosteric modulators for the M1 mAChR have 
already entered clinical trials with allosteric modulators for the other subtypes quickly 
advancing toward the clinic.   
While much progress has been made in developing allosteric modulators of the 
various mAChR for the potential treatment of several CNS disorders, there are still many 
outstanding questions that the muscarinic field is primed to address. First, there is a 
critical need to fully characterize the pharmacological properties important for efficacy and 
adverse effects, in order to derisk clinical candidates and ultimately advance mAChR 
allosteric modulators forward into the clinic with the highest chance of success. This can 
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illustrated by the recent phase II failure of the M1 ago-PAM MK-7622 to significantly 
improve cognitive endpoints in AD patients (74). Better understanding of M1 PAM 
pharmacology at the preclinical research stage may have better informed drug discovery 
decisions and the outcome of Merck’s M1 PAM clinical trial may have been avoided. 
Secondly, through use of M1 PAMs with dramatically different pharmacological properties 
as tool compounds, we as a field can make significant progress in understanding 
muscarinic receptor biology in the CNS.  
  Lastly, characterization of biased allosteric ligands for the M1 mAChR has 
provided useful insight into the mechanism of action of these allosteric modulators. 
However, to date, we have only identified a limited number of biased ligands and more 
focused drug discovery efforts are needed to identify biased ligands for other distinct 
signaling pathways as well as the other mAChR subtypes. Therefore, dedicated medicinal 
chemistry, paired with pathway-specific but still high throughput pharmacological assays, 
is needed to identify a wider range of biased ligands the M1 mAChR. Information gleaned 
from these studies could greatly advance our collective knowledge of mAChR biology as 
well as help inform drug discovery programs. Even modest investments into 
pharmacological characterization of the signaling pathways and pharmacological 
properties involved in allosteric modulator action in vivo could pay huge dividends for drug 
discovery efforts. Through better understanding of the pharmacological properties 
important for efficacy and adverse effects, we as a field can ultimately advance M1 
mAChR allosteric modulators forward into the clinic with the highest chance of success.  
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CHAPTER 5 
MATERIALS AND METHODS 
Calcium mobilization assay 
 Briefly, M1-CHO cells were plated in black-walled, clear-bottomed 384 well plates 
(Greiner Bio-One,Monroe, NC) the day before assay.  The next day, cells were washed 
with assay buffer (Hank’s balanced salt solution, 20 mM HEPES, 4.16 mM sodium 
bicarbonate, and 2.5 mM probenecid) and immediately incubated with 20 μL of 1.15 μM 
Fluo-4-acetomethoxyester (Fluo-4 AM) dye solution prepared in assay buffer for 45 min 
at 37 °C. M1 PAMs were serial diluted (1:3) in DMSO for 10-point concentration−response 
curves (CRC), and further diluted in assay buffer at starting final concentration 30μM 
using Echo liquid handler (Labcyte, Sunnyvale CA).  After removing dye, cells were 
washed with assay buffer. Immediately, calcium flux was measured using the Functional 
Drug Screening System (FDSS7000, Hamamatsu, Japan) The serially diluted 
compounds or DMSO vehicle were added to cells for 2.5 min and then an EC20 
concentration of acetylcholine (ACh) was added and incubated for 2 min. ECmax 
concentration was also added to cells that were incubated with DMSO vehicle to ensure 
the EC20 calcium response. To determine the potency and efficacy of the agonist and 
PAM, data were analyzed to generate a concentration-response curve using a four-point 
logistical equation in GraphPad Prism 5.0 (GraphPad Software, Inc., La Jolla, CA).  
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PLD activity assay 
 Methods were adapted from a previously published procedure (112). Briefly, CHO 
cells stably transfected with the human M1 muscarinic acetylcholine receptor were grown 
on growth media consisted of Ham’s F-12 Nutrient Mix (ThermoFisher #11765), 10% 
FBS, 20 mM HEPES, 1X Antibiotic/Antimycotic, 500 µM G418.  The cells were then plated 
on 6-well plates for a total of approximately 0.7x106 cells / 2mL / well. Plating media 
consisted of growth media without FBS or G418. The following day, plating media was 
aspirated off and labeling media was prepared by adding 3H-palmitic acid (5 µCi/ µL) 
supplemented with 2.08 µg/µL Phosphoethanolamine (PE stock, 25 mg/mL in CHCl3) to 
serum free media supplemented with bovine serum albumin. Each well contained 1mL 
media with 10 to 30 µCi [3H]-palmitic acid. Labeling was allowed to occur in a 37 °C 
incubator overnight. The next morning, the plating media was carefully aspirated off and 
the cells were treated for 5 min with DMSO or M1 PAM then 30 min in the presence of 
0.3% 1-butanol in serum-free assay media (1 mL media/well) or no butanol serum-free 
assay media as a negative control and the plates were incubated at 37 oC. 3H labeling 
efficiency was measured by subtracting the post-labeling medium from the pre-labeling 
medium. All pharmacological agent stocks were used at 500 or 1000-fold higher than the 
final concentration. Immediately after the incubation, 600 µL ice cold acidified methanol 
(1:1 ratio of 0.1 N HCl to Methanol) was added and the cells were scraped off using a cell 
scraper and transferred to a 1.5 mL Eppendorf tube. 300 µL room-temperature CHCl3 
was then added and the sample which was then vortexed vigorously for approximately 
20 seconds. The samples were then spun at 16,000 g for 5 min to separate phases. The 
bottom lipid phase was removed carefully to ensure no other phases were carried over 
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and transferred to a new 1.5 mL Eppendorf tube. The samples were then dried under N2 
gas until all liquid was evaporated. The lipids were then resuspended in 25 µL CHCl3 and 
immediately spotted onto the TLC plate (Sorbtech, Norcross GA; Cat#2315126C). Non-
radioactive lipid standards such as p-Butanol and phosphatidic acid were also spotted on 
the TLC plate. The TLC tank was prepared by placing chromatography paper 7-inch (H) 
x 22.5-inch (W) so that it covers approximately 75% of the tank’s height. The mobile phase 
was then added (10 CHCl3: 2 Methanol: 2 Acetic Acid: 4 Acetone: 1 H20) and allowed to 
equilibrate for 1 hour before the TLC plate was added and run for 1.5 to 2 hours. The 
plate was then removed from the tank and allowed to completely dry before imaging using 
autoradiography film in conjunction with an intensifying screen (BioMax Transcreen LE, 
Carestream Health) and placed in a -80 oC freezer for 3-5 days. The film was then 
processed after exposure and quantified using Chemdoc (Biorad). 
Animals 
 All animal studies were approved by the Vanderbilt University Medical Center 
Institutional Animal Care and Use Committee and were conducted in accordance with the 
National Institutes of Health Guide for the Care and Use of Laboratory Animals. Male 
C57BL6/J mice (Jackson laboratories) and M1 receptor knock-out (KO) mice (with 
permission from J. Wess, National Institutes of Health–National Institute of Diabetes and 
Digestive and Kidney Diseases, Bethesda, MD) were used in electrophysiology and 
behavioral studies (6-10 weeks old). PLD1 knockout (KO) mice (obtained from the trans-
NIH Knock-Out Mouse Project Repository, www.komp.org) maintained on a C57BL6/J 
background were used in electrophysiology studies.  Mice were group housed 4-5 per 
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cage, maintained on a 12 hr light/dark cycle, and food and water were provided ad libitum. 
Adult male Sprague-Dawley rats weighing between 280-350 grams (Envigo, Indianapolis, 
IN) were used in the behavioral studies. Rats were group housed 3 per cage and were 
maintained on a 12 hr light/dark cycle with food and water ad libitum. 
Behavioral manifestations of seizure activity  
 To evaluate induction of behavioral manifestation of seizure activity, C57Bl/6J mice 
received administration of vehicle or 1, 3, 10, 30, or 100 mg/kg M1 PAM. Compounds 
were formulated in 10% Tween 80 (pH 7.0) at a concentration of 10 mg/mL and injected 
intraperitoneally (i.p.) (n = 3). Animals were monitored continuously and scored for 
behavioral manifestations of seizure activity at 5, 10, 15, and 30 min, and 1 and 3 h. 
Behavioral manifestations of seizures were scored using a modified Racine scoring 
system (62, 67). A Racine score of 0 represents no behavior alterations; score 1, 
immobility, mouth and facial movements, or facial clonus; score 2, head nodding, tail 
extension; score 3, forelimb clonus, repetitive movements; score 4, rearing and tonic-
clonic seizure; and score 5, continuous rearing and falling, severe generalized tonic-clonic 
seizure (62, 67, 73). 
Extracellular field electrophysiology 
 6-10 week old male C57BL6/J mice (Jackson Laboratories) were anesthetized 
using isoflurane then transcardially perfused with either ice cold 1)high sucrose cutting 
solution (in mM: 230 sucrose, 2.5 KCl, 8 MgSO4, 0.5 CaCl2, 1.25 NaH2PO4, 10 D-glucose, 
26 NaHCO3), or 2) NMDG-HEPES solution (in mM: 93 NMDG, 2.5 KCl, 1.2 NaH2PO4, 30 
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NaHCO3, 20 HEPES, 25 D-glucose, 5 sodium ascorbate, 2 thiourea, 3 sodium pyruvate, 
10 MgSO4, 0.5 CaCl2, 12 N-acetyl-L-cysteine, pH 7.35, <310 mOsm) and then the brains 
were removed and submerged in ice-cold solution that was the same as the perfusion 
solution (e.g. high sucrose or NMDG solution). Coronal slices containing the prelimbic 
prefrontal cortex were cut at 400 µm and were transferred to a holding chamber 
containing NMDG-HEPES recovery solution (in mM: 93 NMDG, 2.5 KCl, 1.2 NaH2PO4, 
30 NaHCO3, 20 HEPES, 25 D-glucose, 5 sodium ascorbate, 2 thiourea, 3 sodium 
pyruvate, 10 MgSO4, 0.5 CaCl2, 12 N-acetyl-L-cysteine, pH 7.3, <310 mOsm) for 8-10 
minutes at 32 ºC.  Slices were then transferred to a room temperature holding chamber 
for 1.0 hour containing ACSF (in mM: 126 NaCl, 1.25 NaH2PO4, 2.5 KCl, 10 D-glucose, 
26 NaHCO3, 2 CaCl2, 1 MgSO4) supplemented with 600-µM sodium ascorbate for slice 
viability.  All buffers were continuously bubbled with 95% O2/5% CO2. Subsequently, 
slices were transferred to a 30-32 ºC submersion recording chamber (Warner 
Instruments) where they were perfused with ACSF at a rate of 2 mL/min. Recording 
pipettes were constructed from thin-walled borosilicate capillary glass tubing 
(I.D.=1.17 mm, O.D. 1.50 mm; Warner Instruments, Hamden, CT), pulled with a horizontal 
pipette puller (P-97 Sutter Instrument Co., Novata, CA) to a resistance of 1-3MΩ when 
filled with ACSF. Field excitatory postsynaptic potentials (fEPSPs) were recorded from 
layer V of the prelimbic cortex and evoked electrically by a concentric bipolar stimulating 
electrode (200 µs duration, 0.05 Hz; inter-pulse interval of 50 ms) in the superficial layers 
II-III. Layer II/III was visualized using a Olympus BX50WI upright microscope (Olympus, 
Lake Success, NY) microscope according to landmarks illustrated in the Allen mouse 
brain atlas(150) and the recording electrode was laterally placed approximately 200µM 
 88 
away from layer 2/3 into layer V so that the recording and stimulating electrodes were 
parallel to each other. Input-output curves were generated to determine the stimulus 
intensity that produced approximately 70% of the maximum fEPSP slope before each 
experiment, which was then used as the baseline stimulation. Data were digitized using 
a Multiclamp 700B, using a sampling rate of 20,000kHz and were filtered at 0.5kHz, with 
a Digidata 1322A, pClamp 9.2 and Clampex 10.6.2 software (Molecular Devices) running 
on a Dell PC (Round Rock, TX). All test compounds, with the exception of CCh (Tocris 
Bioscience, Bristol, UK) which was diluted in H2O, were diluted to the appropriate 
concentrations in DMSO (<0.1% final) in ACSF and applied to the bath for 20 minutes 
using a peristaltic pump perfusion system. Offline data analysis to calculate fEPSP slope 
was performed using Clampfit 10.2 (Molecular Devices). 
Whole cell electrophysiology  
 Mice were anesthetized with isoflurane then transcardially perfused and the brains 
were removed then as described above. Coronal slices containing either dorsal striatum 
or prelimbic prefrontal cortex (PFC) were cut at 250 µm or 300 µm, respectively, and were 
transferred to a holding chamber containing NMDG-HEPES recovery solution (in mM: 93 
NMDG, 2.5 KCl, 1.2 NaH2PO4, 30 NaHCO3, 20 HEPES, 25 D-glucose, 5 sodium 
ascorbate, 2 thiourea, 3 sodium pyruvate, 10 MgSO4, 0.5 CaCl2, 12 N-acetyl-L-cysteine, 
pH 7.35, <310 mOsm) for 8-10 minutes at 32 ºC.  Slices were then transferred to a room 
temperature holding chamber for 1.0 hour containing ACSF (in mM: 126 NaCl, 1.25 
NaH2PO4, 2.5 KCl, 10 D-glucose, 26 NaHCO3, 2 CaCl2, 1 MgSO4) supplemented with 
600-µM sodium ascorbate for slice viability. All buffers were continuously bubbled with 
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95% O2/5% CO2. Subsequently, slices were transferred to a 30-31 ºC submersion 
recording chamber (Warner Instruments) where they were perfused with ACSF at a rate 
of 2 mL/min. Recording pipettes were constructed from thin-walled borosilicate capillary 
glass tubing (I.D.=1.17 mm, O.D. 1.50 mm; Warner Instruments, Hamden, CT), pulled 
with a horizontal pipette puller (P-97 Sutter Instrument Co., Novato, CA) to a resistance 
of 4-6 MΩ when filled with potassium-based internal solution: (mM) 125 K-gluconate, 4 
NaCl, 10 HEPES, 4 MgATP, 0.3 NaGTP, 10 Tris-phosphocreatine. 
 For the PFC recordings, pyramidal neurons were visualized based on morphology 
with a 40X water-immersion lens with oblique illumination coupled with an Olympus 
BX50WI upright microscope (Olympus). After a stable gigaohm seal was formed, light 
suction was applied to break through the cell membrane and achieve whole-cell access. 
The access resistance was checked at the beginning and the end of each experiment 
and neurons with an access resistance of neurons greater than 30 mOhm were not used 
for analysis. Pyramidal neurons were further identified by their regular spiking pattern 
following depolarizing current injections induced by a series of 500 ms current steps 
(−150pA to +100 pA) incremented in +25 pA performed in current clamp mode. 
Spontaneous EPSCs were recorded at a holding potential of -70 mV (the reversal 
potential for GABAA channels) and the junction potential was not compensated. The 
voltage clamp signal was low pass filtered at 5 kHz and digitized at 10 kHz using a 
Digidata 1322A and acquired using Axon MultiClamp 700B (Molecular Devices, 
Sunnyvale, CA) and controlled by pClamp 9.2 and Clampex 10.6.2 running on a Dell PC. 
After a stable baseline was recorded for 5-10 min, test compounds were diluted to the 
appropriate concentrations in DMSO (<0.1% final) in ACSF and applied to the bath using 
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a peristaltic pump perfusion system. Cumulative probability plots of inter-event-intervals 
(IEI) were constructed using 2 min episodes of baseline and peak effect during drug 
application. In order to determine whether M1 receptor PAM potentiation of sEPSC 
frequency was dependent on PLC, we included 1µM U73122 (Tocris Bioscience, Bristol, 
UK) or DMSO in the internal solution and constantly perfused in 10µM U73122 or DMSO 
(0.2%) ACSF throughout the entire experiment. All sEPSC analyses were performed 
using MiniAnalysis (Synaptosoft Inc., Decatur, GA) or Clampfit 10.2 (Molecular Devices). 
 For striatal spiny projection neurons (SPN) recordings the change in excitability of 
MSN was assessed in current clamp mode by monitoring the change in the number of 
spike discharges in response to a near rheobase depolarization current step (1.5 s). The 
access resistance was checked at the beginning and the end of each experiment, which 
were compensated using “bridge balance”. The change in spike number was calculated 
by averaging the number of spikes during the baseline subtracted from the peak drug-
effect (60 seconds). Offline data analysis to calculate change in SPN excitability was 
performed using Clampfit 10.2 (Molecular Devices). 
Novel object recognition task  
  Rats were habituated for 10 min for 2 consecutive days in an empty novel object 
recognition arena consisting of dark-colored plexiglass box (40 × 64 × 33 cm3). On day 
3, rats were administered vehicle 0.5% methylcellulose (for MK-7622 and 20% b-
cyclodextrin for VU0453595) or M1 PAM (0.3−10 mg/kg, per os (p.o.), 3 mL/kg, n = 11-
12) and returned to their home cage for 90 min. Rats were then placed in the novel object 
recognition arena containing two identical objects for 10 min. Following the exposure 
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period, rats were placed back into their home cages for 24 h. The rats were then returned 
to the arena in which one of the previously exposed (familiar) objects was replaced by a 
novel object and were video recorded for 5 min while they explored the two objects. Time 
spent exploring each object was scored by an observer blinded to the experimental 
conditions and the recognition index was calculated as [(time spent exploring novel 
object) − (time spent exploring familiar object)]/total time exploring objects. 
In vivo pharmacokinetic analysis 
VU0405652 and VU0405645 compound were formulated as 10% Tween 80 in sterile 
water at the concentration of 3 mg/mL and administered intraperitoneally to male 
C57/bl6J mice and dosed at 10 mg/kg. Mice blood (cardiac puncture) and brain were 
collected at 15 and 30min. Animals were euthanized and decapitated, and the brains were 
removed, thoroughly washed in ice-cold (4 °C) phosphate-buffered saline, and 
immediately frozen on dry ice. Brain samples were processed and concentrations of 
compound were determined via electrospray ionization on an AB Sciex API-4000 (Foster 
City, CA) triple-quadrupole instrument that was coupled with Shimadzu LC-10AD pumps 
(Columbia, MD) and a Leap Technologies CTC PAL auto-sampler (Carrboro, NC). All 
data were analyzed using AB Sciex Analyst 1.5.1 software. Compound exposures, in the 
form of area-under-the-curve were calculated by trapezoidal method employing PRISM 
software (GraphPad, La Jolla, CA). 
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Western blot analysis of PLD1 protein 
Total protein was extracted from the cortex of PLD1 KO mice and littermate controls by 
homogenization in RIPA buffer (Sigma) with protease inhibitors. After homogenization, 
samples were spun for 20 min at 15,000g at 4 °C. The supernatant was kept and protein 
concentration was determined using a bicinchoninic acid (BCA) protein assay (Pierce). 
50 μg protein per sample was electrophoretically separated using a 4–20% SDS 
polyacrylamide gel and transferred onto a nitrocellulose membrane using the iBlot2 
(Thermo Fisher). The membrane was blocked with Odyssey blocking buffer (LI-COR) for 
1 h at room temperature. Membranes were probed with the following primary antibodies: 
rabbit anti-PLD1 (1:500, Cell Signaling Technology #3832) and mouse anti-tubulin 
(1:5000, Abcam ab44928) overnight at 4 °C. Membranes were washed with TBST (25 
mM Tris, 150 mM NaCl, 0.05% Tween 20) and incubated with fluorescently labeled 
secondary antibodies (Goat anti-rabbit 800 and goat anti-mouse 680, 1:5000, LI-COR) 
for one hour at room temperature. Blots were washed again and imaged using a LI-COR 
Odyssey 
Statistical analyses  
For the novel object recognition task groups were compared using a one-way analysis of 
variance (ANOVA), followed by Dunnett’s multiple comparison tests with the vehicle 
treated rats as the control group. Changes in sEPSC frequency before and during drug 
add (peak effect) was compared using a paired t-test after data passed the Kohmogrov-
Sminov normality test. For LTD experiments where only 2 experimental conditions were 
compared, a paired t-test was performed to calculate statistical significance after data 
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passed the Kohmogrov-Sminov normality test. For electrophysiological comparisons with 
more than one group, a one-way ANOVA was performed followed by Dunnett’s Multiple 
Comparison test. For all statistical comparison, the critical p value was considered to be 
0.05. The numbers of animals to be used for each experiment outlined within the 
manuscript were determined using a power calculation statistical analysis using the 
Power and Sample Size Calculation software program available at Vanderbilt University 
(Dupont and Plummer, PS Controlled Clinical Trials. 18:274 1997). Animal numbers are 
based on a power calculation using standard errors from published studies and previous 
experience to detect >20% difference for each outlined experiment with an 80% power 
(alpha=0.05, power=80%, delta=0.2, sigma=0.18).   
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